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 ABSTRACT 
 
 
Aim: To analyse the dosimetric effects of density changes, calculation curve errors and 
geometric errors in proton dose distributions. 
Methods: Single field optimized treatment plans were created on homogenous and 
heterogeneous water phantoms. Intensity modulated craniospinal treatment plans were 
created on CT image data sets from 6 pediatric patients. Setup errors were simulated by 
shifting the isocenter for ±1 to ±5 mm along the x-, z-and y-axis. Calibration curve errors 
were simulated by increasing or decreasing the relative stopping power by 1% to 5%. 
Density changes were simulated by introducing bone and air in the beam path.  
Result: Air and bone resulted in a change in proton range with a factor of +0,94 and – 
0,48, respectively. The V95% was >97% for the CTV regardless of any setup-and calibration 
curve error, though hotspots and cold spots occurred in the brain. A 3% overshoot caused 
an increased of 47% in the Dmean for the thyroid.  
Conclusion: Density changes caused severe alterations of the proton range. Error-induced 
dose disturbances emerged mainly in areas of complex tissue heterogeneities. Following 
setup-and calibration curve errors, significant dose escalation were observed for organs at 
risk in close proximity to the target volume.  
 
Keywords: radiotherapy, proton, active scanning technique, intensity modulated proton 
therapy, IMPT, range uncertainty, density changes, setup errors, craniospinal irradiation, 
pediatric. 
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1 INTRODUCTION 
1.1 Radiation therapy 
Radiation therapy plays an important role in the fight against cancer, either as the preferred 
primary treatment or adjuvant to surgery and/or chemotherapy. Conventional radiotherapy 
with photons and electrons are well known and established modalities. During the last 
decades the radiation treatment technology has evolved rapidly. With the development of 
advanced treatment delivery techniques like Intensity Modulated Radiation Therapy 
(IMRT) (1) and Volumetric Modulated Arc Therapy (VMAT) (2), highly sophisticated 
treatment plans can be designed and delivered. Less common than conventional 
radiotherapy with photons is radiotherapy with protons. The use of protons in cancer 
treatment was proposed by Robert R. Wilson in a paper published in Radiology as early as 
1946 (3), and used for cancer treatment for the first time 8 years later at the Lawrence 
Berkeley Laboratory. Today proton therapy is the subject of increasing interest, both 
worldwide and in Norway. Norway is at present in the beginning of the planning stage in 
preparing of several regional proton therapy facilities. Globally there are approximately 40 
proton centers in operation, and several more are under construction and in the planning 
phase. As of the end of 2012 around 94 000 patients have received radiotherapy with 
protons (4).  
 
The main goal of any radiation therapy technique is to deliver sufficient high dose to kill 
the tumor cells and at the same time spare normal organs and healthy tissue as much dose 
as possible. The main rationale for using proton beams in cancer treatment is for the most 
part its favourable physical properties; the deposition of the major proportion of the dose 
within a few millimetres in a well defined depth (the Bragg Peak), followed by a sharp dose 
fall-off and a subsequent negligible dose deposition thereafter. This allows for sparing of 
normal tissue and organs at risk, and at the same time achieve adequate target dose 
coverage and dose conformity. Typical treatment sites for which applying proton therapy is 
considered advantageous are the central nervous system, the lungs, the gastrointestinal 
canal, for the prostate, for ocular melanomas, for head and neck and for paediatric cancers. 
When it comes to the clinical evidence of proton therapy, current data are not sufficient to 
conclude that the proton therapy is superior to over conventional radiotherapy for most 
diagnosis. For chordomas, however, there is evidence for better outcome with protons 
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compared to photons; this also applies for ocular melanomas. For prostate and 
hepatocellular carcinoma there is evidence for the efficacy of proton therapy, but not 
enough to claim that this modality provides a better standard of care than advanced photon 
therapy techniques. For malignancies in the Central Nervous System (CNS) in paediatric 
patients, the results are promising, but here also still too few clinical trials have been 
conducted and one cannot yet conclude (5). However, dose planning studies performed 
with the intention to compare proton and photon dose distributions, clearly demonstrates 
superior normal tissue sparing, decreased integral dose with protons and excellent dose 
coverage, especially in the treatment of the brain and the spinalcanal (craniospinal 
irradiation) (6, 7). The latter is important, considering that the risk of late effects and 
second cancer is dose dependent, and well documented for this patient group (8).  
 
Thus, proton therapy may offer treatment plans with improved dose conformation to the 
target volume, sparing of critical structures and reduction of integral dose to healthy tissue. 
However, in proton therapy several uncertainties exist that have to be addressed both 
during planning and execution of the treatment. Proton therapy is, as photon therapy is, 
commonly planned based on information from Computer Tomography (CT) images. A CT 
scan yields cross-sectional images based on the absorption of x-rays, and provides images 
of high quality with detailed anatomical information, as well as a “map” over the tissue 
densities in the scanned volume (9). The CT scan is acquired with the patient in the 
treatment position and is used for the delineating of the treatment planning volumes, and 
for computing the depth of the proton penetration (proton range) in the patient, used for 
the calculation of the dose distribution in the patient. During execution of the treatment, 
the goal is to exactly reproduce the situation present at planning, but in every clinical 
situation, variations occur treatment (10, 11). Unless accounted for, any inaccuracy in the 
estimation of the proton range in the patient, inaccuracies in the patient positioning (setup 
errors), patient- and/or organ motion and anatomic changes during the radiotherapy 
course (weight loss, tumor shrinkage etc.) could lead to severe alterations of the planned 
dose distribution (12-14). 
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1.2 Aim and research questions 
The main aim of this work has been the investigation and quantification of the potential 
alteration of proton dose distributions in phantoms and in patient geometries in the 
presence of  
1) Geometric errors, 
2) Proton range estimation errors and 
3) Tissue density changes in the beam path. 
 
The study is divided into a theoretical part and a clinical part.  
The theoretical part is a simulation study performed on water phantoms.  
The clinical part is a robustness analysis of craniospinal treatment plans.  
 
1.2.1 Water phantom dose calculations 
The following research question were investigated in the water phantom study:  
 
I. How does a change of tissue composition in the beam path affect the proton 
particle range and the depth dose distribution?  
II. How do geometric errors affect the proton dose distribution in homogenous and 
heterogeneous water phantoms? 
 
1.2.2 Robustness analysis of craniospinal treatment plans 
The following research questions were investigated in the robustness analysis:  
 
I. How do range estimation errors affect the doses to the target volume and organs at 
risk? 
II. How do setup errors affect the doses to target volumes and the organs at risk? 
 
 
 
 
1.3 Structure of the thesis 
This thesis is structured in the following way: Chapter 2 presents the theoretical 
background, here radiation physics, biology and technical aspects are presented, the 
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treatment planning process is thoroughly described and the problem of uncertainty in 
proton therapy is introduced and discussed. Chapter 3 describes the study and the 
simulation procedures. In chapter 4 the results are presented. A discussion of the results in 
relation to theory and previous research is done in Chapter 5. Chapter 6 contains the 
conclusion and possible clinical implications.  
 
The author performed all the proton treatment planning and uncertainty simulations in this 
thesis. Unless otherwise specified all figures were produced by the author. 
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2 THEORY 
2.1 Radiation physics and biology  
2.1.1 The physical properties of photon beams 
A photon is considered as massless and carries no electric charge. When a photon beam 
traverses matter interactions will occur and lead to energy being transferred from the 
radiation to the irradiated material. The most common interaction processes that 
contribute to energy absorption when irradiating matter with photons are the Photoelectric 
Absorption, the Compton Scattering and Pair production.  
 
2.1.1.1  The Photoe le c tr i c  Effec t  
The Photoelectric Effect is an inelastic collision between an incoming photon and an 
atomic electron. The process can occur if the photon energy is equal or larger than the 
binding energy of the orbital electron. The photon will be absorbed and transfer all its 
energy to the electron in the process. The electron is then ejected from the atom. The 
probability for this interaction to take place depends on the atomic number of the 
irradiated material and the photon energy. The probability increases with increasing atomic 
number and decreases with increasing photon energy (15, p. 441).  
 
2.1.1.2  Compton Scatter ing 
Compton Scattering occurs when an incoming photon interacts with an atomic orbital 
electron and being only partially absorbed in the process, so that both a photon and an 
electron is scattered out from the atom. The probability (the cross-section) for Compton 
scattering increases when the energy of the incoming photon is substantially higher than 
the involved electron’s binding energy. The result of a Compton scattering process is that, 
in addition to the ionization of the atom, a scattered photon with lower energy than the 
incoming photons energy is emitted. The probability that this process take place is strongly 
dependent on the electron density of the irradiated material (15, p. 445).  
 
 
 11 
2.1.1.3   Pair  Product ion 
In this process the incoming photon interacts with the field from an atomic nucleus and all 
its energy is absorbed as an electron and positron is produced. For Pair Production to take 
place the photon energy must be at least 1,022 MeV (two times the rest mass of the 
electron), in order to enable the creation of an electron-positron pair. In this process the 
incoming photon interacts with the field from an atomic nucleus and all its energy is 
absorbed when an electron and positron is produced. The probability that this interaction 
occurs is a function of increases with a higher atomic number and photon energy (15, p. 
449).  
 
 
2.1.1.4  Beam attenuat ion 
The interaction processes described above will be the main contributors to an attenuation 
of the intensity of a photon beam traversing through a medium, as photons from the 
incoming beam interacts with matter and their energy is either totally or partially 
transferred to the medium. The beam attenuation is described by 
 
 𝐼(𝑥) = 𝐼!!!"         (Equation 2-1) 
 
with I0 being the incident beam intensity, x being the absorber thickness, µ being the linear 
attenuation coefficient of the irradiated material and I(x) being the beam intensity at a 
certain depth x in the traversed matter. The attenuation of a photon beam is illustrated in 
Figure 2-1, which shows the depth dose curve for 6 MV and 18MV photon beams. As the 
photon beam enters a material there will be a dose build up region in which the dose 
increases until it reaches a dose maximum in a certain position in depth. The position in 
depth of the dose maximum is dependent on the beam energy. Beyond this dose maximum 
the dose will gradually decrease in depth as a function of the interactions between the 
incoming photons and the structure and composition of the traversed medium.  
 
 
 12 
 
Figure 2-1: Measurements of photon beams at Haukeland University Hospital: The depth dose distribution for 6 MV and 
15 MV photon beams (16).  
 
 
 
2.1.2 The physical properties of proton beams 
A proton is a subatomic particle with a positive elementary electrical charge (+ 1 e). When 
an electrically charged particle is traversing matter, two main effects occur in general; due 
to the numerous interactions with the atomic electrons and nucleons in the traversed 
matter the particle will a) lose energy and b) be scattered from its original path.  
 
 
2.1.2.1  Energy loss  and Stopping Power 
The proton loses its energy primarily through inelastic collisions with the orbital electrons 
of atoms in the matter it traverses. These collisions result in either ionizations or 
excitations of the atoms, and in these processes, energy is transferred from the proton to 
the matter, which thus is the absorber of energy and dose. The averaged energy loss per 
unit path length that a proton beam experience when penetrating matter is described by the 
quantity Stopping Power: !"!"  (MeV/cm) and this is given by the Bethe-Bloch formula:   
 
 − !"!" = 2πN!r!m!c!ρ !! !!!! ln !!!!!!!!!"#!! − 2β! − δ − 2 !!         (Equation 2-2)   
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Table 2-I: Parameters and definitions in the Bethe-Bloch formula describing energy loss of charged nuclei in matter. 
	   	  
Symbol Definition 
re Classical electron radius = 2.817 x 10-13 cm 
me Electron mass = 0.511MeV/c2 
Na Avogadro’s number = 6.022 x 1023 mol-1 
I Mean excitation energy (eV) 
Z  Atomic number of absorber 
A Atomic weight of absorber (g/mol) 
ρ Density of absorber 
z Charge of incident particle in units of e 
β = v/c of incident particle (speed of particle relative to c) 
γ 1/√ (1-β2) 
Wmax Maximum energy transfer in a single collision 
δ Density correction 
C Shell correction 
 
 
 
 
Table 2-I presents the definition of the parameters in the Bethe-Bloch equation. The 
energy loss is dependent on the properties of the traversing particle like the mass, the 
electrical charge, and its velocity, as well as the properties of the absorbing media like 
density, atomic weight and atomic number (17). Thus, for a proton beam traversing a 
material the energy loss can, as an approximation, be described as being proportional to the 
mass of the material and inversely proportional to the square of the velocity of the 
incoming proton: 
  
 − ∆!∆!~ !!!        (Equation 2.3) 
 
 
 
In Figure 2-2 the proton Stopping Power is displayed as a function of particle energy. The 
figure shows the proton stopping power curves for protons traversing i) water, ii) compact 
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bone and iii) air. The region of the energies typically used in proton therapy, the range 
between 70 MeV- 275 MeV, is marked with grey.  
 
 
 
 
 
 
Figure 2-2: The Proton Stopping Power as a function of energy for i) water (blue line), ii) compact bone (red line) and iii) 
air (green line). The marked grey area is the energy levels used for patient treatment. The plot is based on PSTAR data 
from (18). 
 
 
 
The energy loss experienced by a particle traversing through matter will be dependent on 
the density and composition of the traversed matter, as we have seen. By normalizing the 
energy loss with respect to the mass of the traversed medium, one obtains a mass 
independent measure of the Stopping Power; the so-called Mass Stopping Power. The 
Mass Stopping Power expresses the average energy loss corrected for mass in units of 
MeV/g cm-2 and is defined as: 
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− !"!" = !! !"!"         (Equation 2.4) 
 
 
where 𝜌𝑑𝑥 is the mass thickness (g/cm2). The dependence on the absorber density is 
largely removed when the energy loss is expressed by the Mass Stopping Power. 
Consequently, the energy loss expressed in terms of mass thickness will vary little for the 
majority of materials involved in radiation therapy (17).  
 
 
2.1.2.2  Multiple  Coulomb Scatter ing  
When an elastic interaction between a traversing proton and one of the atomic nuclei in the 
traversed material occurs, the proton particle will experience a very small deflection and 
almost no energy loss. The deflections from numerous interactions as the proton traverses 
the material, entails that the protons is scattered from a straight path. The amount of 
scattering is dependent on the atomic weight of the scattering material; a high Z-material 
scatters more strongly than a low Z-material (19). 
 
 
2.1.2.3  The range and range s tragg l ing  
The distance a particle travels in a material before it loses all its energy is called the range. 
The range of a proton is strongly dependent on the particle energy and the absorber 
material.  Specifically, the depth of penetration is proportional to the square of the proton 
energy and scales with !! of the traversed material. The energy and absorber dependency is 
illustrated in Figure 2-3, which shows the range particle as a function of energy for a 
proton traversing i) water, ii) compact bone and iii) air.  
 
Assuming that the energy loss a particle experience is continuous, the penetration in depth 
for a monoenergetic proton beam must be well defined. However, protons of a given 
energy do not experience an exact identical set of interactions when traversing matter, and 
therefore do not experience the same amount of energy loss; there will be an energy 
straggling. Consequently there will be a distribution of ranges for protons in a proton beam 
around an averaged value, rather than one sharp finite range, a phenomenon known as 
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range straggling (17). The uncertainty in proton range associated with the range straggling 
scales with the depth traversed and is approximately 1,2 % of the projected range (20, p. 
36). 
 
 
 
 
Figure 2-3: Proton particle range in i) water (blue line), ii) bone (red line) and iii) air (green line). Energy (MeV) is 
displayed on the x-axis and range (cm) on the y-axis. The plot is based on data (measurements) from (18). 
 
 
 
2.1.2.4  The pris t ine Bragg peak 
In Figure 2-4 the depth dose curve for 107 MeV protons is displayed. As the Bethe-Bloch 
equation shows, the rate of energy loss is approximately inversely proportional to the 
square of the velocity of the traversing particle. This means that in the entrance region of 
the beam path, where the particle energy and velocity is at its greatest, the energy 
deposition is small. As the particle traverses the matter and experiences numerous 
interactions, the velocity of the particle decreases, which in turn causes the probability of 
ionizations and excitations to increase. Consequently, towards the end of its range, the 
energy deposition for a charged particle increases rapidly and reaches a maximum, called 
the Bragg Peak, after which the dose is negligible as the particle comes to rest in the tissue. 
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The position in depth of the Bragg Peak in any material is directly proportional to the 
initial energy of the particle (19).  
  
 
 
 
 
 
Figure 2-4: FLUKA Monte Carlo simulations: The depth dose curve in water for 107 MeV protons. The Figure shows 
that the dose deposition is low at the entrance region, and then increases rapidly towards the end of the particle range, 
and then a maximum dose deposition in the Bragg Peak before the protons come to rest. The image is from (16). 
 
 
 
2.1.3 The Linear Energy Transfer 
The ionization density, produced by ionization radiation in tissue is expressed in terms of 
the entity the Linear Energy Transfer (LET) of the ionizing beam. The LET expresses the 
linear rate of energy transferred from the beam to an absorbing media and is given by 
keV/µm;  
 𝐿𝐸𝑇 !"#!" = !"!"       (Equation 2.5) 
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where dE is the average energy locally imparted to the medium by a charged particle of a 
specified energy traversing a distance of dx in the material. The associated LET value of a 
certain beam particle will thus describe the quality of the beam in terms of its ionization 
capacity. Different types of beam particles will have different LET values, and the different 
particles are divided into two main categories; high LET particles (densely ionizing) and 
low LET particles (sparsely ionizing) (21). Protons are low-LET radiation with a relatively 
low ionization density at the beginning of their entrance, at the surface of the matter. The 
LET capacity is strongly coupled to the Stopping Power, thus it varies with and 
proportional to the velocity of the particles and varies consequently with the depth in 
matter. Along the particle path, the ionization density increases first slowly, then rapidly 
near the end of the beam range, thus forming a quite narrow region of high ionization 
density in the Bragg peak area (19, p. 21).   
  
 
2.1.4 Absorbed dose and the RBE-weighted absorbed dose 
Absorbed dose (D) is defined as the amount of energy absorbed per unit mass of the 
matter irradiated. It is expressed by the formula:  
  𝐷 = ∆!∆!        (Equation 2.6) 
 
In this equation ∆E reflects the energy deposited by ionization radiation to a unit of mass 
∆m. The dose is expressed in Gy (Joule/kg ) (22, p. 72). The same amount of physically 
deposited dose from different types of radiation does not necessarily produce an equal 
biologic effect in the irradiated tissue. The eﬀect ionizing radiation have in a specific 
biological material is LET dependent, and also influenced by factors such as the dose and 
the individual energy of the irradiating beam particles amongst, other. The ratio between 
the biological effectiveness of two different types of ionization radiation is defined as the 
Relative Biological Effectiveness (RBE) and this is expressed by  
 𝑅𝐵𝐸 = !!!!         (Equation 2.7) 
 
Here the Dx is the dose from a radiation of a reference particle type (i.e. photons), and the 
DR is the dose of the radiation with particle type R (e.g. protons) that causes the same 
 19 
amount of biological damage as the reference radiation type (23, p. 261). Compared to 
photons, protons have a somewhat higher biologically effectiveness. This means that a 
lower dose with proton therapy is needed to cause an equal biological effect as that 
originating from photons. To define what dose from protons that will produce an identical 
biological effect as a certain dose from photons, given otherwise identical conditions, the 
RBE-weighted dose is defined as: 
 𝐷!"# = 𝑅𝐵𝐸×𝐷       (Equation 2.8)  
 
In this equation the DRBE is the RBE-weighted dose and the D is the physical proton dose 
in Gy. The unit of the RBE-weighted dose is Gy(RBE), which is applied in order is to 
distinguish between physical dose and RBE weighted dose (23, p. 261). The RBE-weighted 
dose is needed for comparisons of the effect of photon vs. proton irradiation, for the 
selection of appropriate proton doses and the prediction of therapeutic outcomes based on 
previous clinical experience with photons. It is well known that the RBE is not a fixed 
value, but varies over the physical depth dose curve, and also varies with tissue type and 
with the fraction size (23, p. 262). The use of a single (generic) RBE value of 1.1 for clinical 
use is, however, still recommended by ICRU, as expressed in ICRU report 78 (19, p. 28). 
 
 
2.2 Photon beam production and delivery techniques 
The two main elements of a linac are the beam producing component and the delivery unit: 
a rotating gantry (360°). In the beam producing part, electrons are injected and accelerated 
with an electric field. In photon mode, a metal target is inserted into the accelerated 
electrons’ beam path, resulting in the production of bremsstrahlung x-rays in this target, 
the photon field further collimated from the target and onwards, towards the patient. In 
electron mode, the metal target is not applied and the electron field is collimated from the 
exit of the accelerating structure onwards, towards the patient. In the gantry, the beam is 
shaped on its way towards the patient by metal collimators, and shaped to the target 
volume by movable collimator jaws, so called Multi Leaf Collimators (MLC’s) or metal 
blocks and extended electron collimators, to a distance only a few centimetres away from 
the surface of the patient. Other components of a linear accelerator treatment unit are the 
treatment coach and the image guidance devices. At modern linacs 2D and 3D image 
guidance equipment are integrated as a part of the treatment machine (24, p. 86).  
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In advanced radiotherapy the dose distribution is normally planned based on a definition of 
volumes of interest in a 3DCT image dataset, and delivered by 3-Dimensional Conformal 
Radiation Therapy (3DCRT), by Intensity Modulated Radiation Therapy (IMRT) or as 
Volumetric Modulated Arc Therapy (VMAT). The least sophisticated technique amongst 
these three, the 3DCRT, applies a highly conformal dose distribution delivered by a 
number of open fields of uniform intensity or by wedged fields applying a simple 
modification of the beam fluence across the field. The dose distribution is generated by so-
called forward treatment planning, where the number of fields, the field angles, the field 
shaping by MLC or blocks and the field weighting are manually chosen by the user, and 
thereafter the dose distribution is calculated (25, p. 266). The IMRT and the VMAT 
techniques utilizes an invers treatment planning approach, where, the dose distribution is 
generated based on an initial optimization of several beam parameters in order to achieve a 
pre-determined goal for the plan through a set of predefined dose volume constraints and 
objectives. Both the VMAT and IMRT techniques have the capacity to deliver concave 
dose distributions and at the same time provide sparing of normal tissue through an 
optimization of the beam fluence given a set of fields to be applied. IMRT is delivered field 
by field with fixed gantry positions; either by multiple segments shaped by the MLCs (step-
and –shoot or segmental MLC) or by pairs of opposing MLC leaves swiping across the 
fields (sliding window or dynamic MLC) (1). VMAT is the most complex and advanced 
technique in photon therapy.  The dose distribution is delivered while the gantry is rotated 
around the patient, thus the name Arch Therapy is also applied for this technique. The 
dose rate, the gantry speed, the MLC shape; the opening and swiping –orientation, are 
parameters that are varied during the rotation of the gantry (26). 
 
 
2.3 Proton beam production and delivery techniques  
In Figure 2-5 the different parts of a proton treatment facility is shown. The production of 
the proton beam takes place in a particle accelerator, with a cyclotron or with a 
synchrotron [1] that can accelerates the beam particles to the energy level sufficient for 
treating deep-seated target volumes. Most common accelerators for proton therapy 
worldwide are cyclotrons, which produce high intensity beams with fixed energy. 
Synchrotrons that produce beams with pulsed energy are larger and not so widely applied 
in proton therapy facilities, however, at facilities offering carbon ion treatment, the 
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accelerators are synchrotrons. Magnets in the beam transport lines [2] are used to steer the 
beam into the treatment rooms. The treatment is delivered using rotating gantries [3] or by 
using horizontal or vertical fixed beam lines [4]. As for photon treatment rooms, at proton 
facilities, the treatment rooms also include a (robotic) treatment coach, as well as image 
guidance equipment.  
 
Two main treatment techniques exist today for the deliverance of proton therapy: i) the 
passive scattering technique and ii) the active scanning technique, with the passive 
scattering technique being the most common technique as of 2014. Most emphasis is at 
present placed on the development of the active scanning technique, and it is expected that 
this technique will be the main delivery technique in the future. 
 
 
 
 
 
Figure 2-5: Schematic overview over a proton therapy facility which displays 1) the accelerator, here a cyclotron, 2) the 
transport beam lines, 3) the treatment rooms with rotating gantry and 4) the treatment room with fixed beam. Image 
from (27). 
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2.3.1 Range modulation: the Spread Out Bragg Peak 
The output from the particle accelerator is a quite narrow near-monoenergetic beam of 
protons, a so-called pencil beam, which when penetrating matter forms a pristine Bragg 
Peak which is not wide enough in depth to cover most treatment volumes (see Figure 2-4). 
In order to deliver proton beams suitable for treating patients, the beam has to be shaped 
and modulated, and importantly, it has to be broadened in depth, in the beam direction 
through a patient. This is accomplished by combining several pristine Bragg Peaks of 
varying energy (range) and sum up their contributions to a treatment beam by applying a 
relative weight for each pristine Bragg Peak. The net result of this composition is a spread 
out dose plateau region referred to as the Spread Out Bragg Peak (SOBP). For the passive 
scattering technique the range modulation results in a flat SOBP, illustrated in Figure 2-6, 
providing a uniform high dose plateau across the field. The active scanning techniques can 
accomplish arbitrary shapes of the SOBP curve due to the individual optimizing of each 
pristine Bragg Peak, thus creating a non-uniform high dose plateau across the field, as 
illustrated in Figure 2-7 (28).   
 
 
 
 
 
Figure 2-6: A flat Spread Out Bragg Peak (SOBP): Pristine Bragg Peaks of different weights are superimposed in order to 
form a flat SOBP with the highest weighted Bragg Peaks positioned deepest, providing in sum a uniform SOBP dose 
plateau (along the beam axis.) (28). 
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Figure 2-7: A non-uniform Spread Out Bragg Peak (SOPBP): Individually and optimally weighted pristine Bragg Peaks 
are superimposed in order to form a non-uniform SOBP dose plateau. Here the weighting of the Bragg Peak is increased 
at some depth due to the integrated boost in the middle of the SOBP (28). 
 
 
 
2.3.2 The Passive Scattering technique 
When applying the passive beam delivery technique, also called the scattered beam 
technique, range modulators, scattering foils, blocks, and compensators are used to 
modulate and shape the beam in order to tailor the dose to the shape of the target volume. 
The principle of the passive scattering technique is illustrated in Figure 2-8. The 
broadening of the beam laterally to cover the whole target homogeneously is most 
commonly achieved by a double-scattering system where the beam is broadened out to the 
required field size in two scattering steps. A uniform SOBP is formed by letting the 
incident proton beam sequentially penetrate absorbers of varying thickness (the passive 
range modulator technique) each absorber thickness applied in a dose plan calculated 
fraction of the total irradiation time. An additional range shifter is normally applied in 
order to shift the whole SOBP does plateau to the desired depth if required. This means 
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that the entire SOBP is positioned in a region where it covers the target volume from the 
most distal to the most proximal depth. For optimal beam shaping, patient- and field 
specific physical devices are necessary. Blocks are used to limit and adapt the lateral 
boundaries of each treatment field to fit the target volume, while beam absorbing 
compensators are designed to conform the dose the distal edge of the target volume (29).  
 
 
 
 
 
 
 
Figure 2-8: The principles of the passive scattering technique. The narrow proton beam is scattered out laterally by high Z 
material scatter foils, and range modulated by the use of low Z material in order to create the SOBP plateau.  The 
compensator conforms the dose to the target distally, while patient specific blocks define the aperture. Image from (16). 
 
 
 
2.3.3 The active scanning technique 
The active scanning technique is the other main method for delivery of proton therapy.  
This method takes advantage of the fact that protons have an electrical charge, and 
therefore can be steered and deflected by magnets. By precision steering of a number of 
laterally deflected energy modulated proton pencil beams, a target volume can be scanned 
in 3 dimensions. In Figure 2-9 the principles of active scanning is illustrated. The target 
volume is divided into layers of equal energy (iso-energy layers), which, due to the different 
densities in the patient not necessarily are in the same plane. The deepest layer, which 
requires the highest beam energy, is scanned first, then the beam energy is reduced and the 
next layer is scanned and so on, until all layers have been delivered. The scanning of each 
layer can be done by e.g. so-called discrete spot scanning technique. In discrete spot 
scanning the dose is delivered to so-called spots, which are pristine Bragg peaks 
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characterized by its range, intensity and size (30). Compared to the passive scattering 
technique, the active scanning technique has several advantages. Firstly, because the dose 
distribution can be shaped and tailored to the target without any physical absorbers or 
patient specific compensators or blocks, the amount of nuclear interactions that occur in 
the physical devices are significantly reduced, and therefore the production of neutrons 
outside the patient is reduced accordingly. Moreover, the additional dose often seen 
proximal for the target volume when applying the passive technique, can with the active 
technique be avoided. Secondly, the scanning technique also facilitates great flexibility, 
which can be fully utilized in Intensity Modulated Proton Therapy (IMPT). The 
disadvantage with the active scanning technique is that the treatment plans and the active 
scanning treatment often are more sensitive to changes in the patients anatomy and to 
patient and target volume motion, compared to treatment plans with the passive scattering 
technique (31). 
 
 
 
 
 
Figure 2-9: An active scanning technique: The principle of the spot scanning technique. Pencil beams applied in discrete 
steps deliver the dose. The proton source is interrupted after each pencil beam is delivered, the beam-steering elements 
are changed to deliver protons at a different position and/or energy, and the beam is turned back on until the desired 
number of protons has been delivered. Image from (32). 
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2.4 The treatment planning process for proton beams 
The radiotherapy treatment planning process involves several stages, including the 
acquisition of the planning CT, the volume delineation in the CT images, the design of the 
treatment plan, and the calculation of the dose distribution and the evaluation of the 
treatment plan.  The design of a proton treatment plan includes the choice of field 
arrangements, such as the number of field and the field angles, the assigning of the dose 
prescription and the dose fractionation, the choice of optimization methods, the use of 
beam modifying devices and the margin definitions. This section provides a description of 
these various steps, based upon the planning methodology in the Eclipse™ proton 
treatment planning system. 
 
2.4.1 CT imaging, Hounsfield Units and the calibration curve 
Computer Tomography (CT) is the standard imaging modality for treatment planning in 
proton therapy. A CT image dataset provides detailed 3D information of the patient’s 
anatomy, as well as information about the tissue density in the scanned patient volume. In 
CT images the density of a specific volume of tissue is given by what is known as the 
Hounsfield Units (HU). The HU is a numeric representation of the mean measured x- ray 
attenuation in each voxel in the scanned volume. The relationship between the linear 
attenuation coefficient (µ) and the HU value is given by  
 
  𝐻𝑈 =    !!"##$%!!!"#$%!!"#$% ×  1000      (Equation 2.9) 
 
 
Here the 𝜇!"##$% and 𝜇!"#$% represent the linear attenuation coefficients of the irradiated 
tissue and water respectively.  The HU value of a tissue is however not absolute, it will be 
influenced by the applied x-ray energy, the reconstruction filter, the slice thickness and the 
presence of image artefacts like for instance the partial volume effect (9).  
 
The planning CT images serves two purposes; firstly, it is used to define the anatomic and 
geometric structures that are of significance for the radiation treatment. Secondly, the CT 
image dataset is used to estimate the proton range in the patient used when calculating the 
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dose distribution. To do this, the HU values have to be converted in to relative proton 
stopping power using a calibration curve. The purpose of the calibration curve is to 
establish a correlation between the HU values of the human tissue, and the relative 
stopping power.  To generate a calibration curve, the relative stopping power is calculated 
for a large number test materials of human tissue of known chemical composition, this 
using a simplified version of the Bethe-Bloch formula. The corresponding measured HU 
value from the test material is then plotted against the theoretically computed relative 
stopping power values. Several linear lines are fitted to the plotted data, each line extends 
over a limited number of HU values, as displayed in Figure 2-10. The final calibration 
curve is normally a combination of linear fitted curves from data containing information 
from attenuation in lungs, soft tissue and bone (19, 33).  
 
 
 
 
 
 
Figure 2-10: Calibration curve with the relation between Hounsfield Units and Relative Stopping Power: The calibration 
curves obtain by the stoichiometric method. The enlarge graph displays the soft tissue group split into five linear curves. 
The image behind shows the final calibration curve generated from a combination of the three linear fitted curves for 
lung tissue, soft tissue and bone tissue. Image from (34). 
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2.4.1.1  Range uncertaint ies  assoc iated with the CT cal ibrat ion curve  
The level of precision with which one can determine the stopping power in the patient is 
directly dependent on the accuracy of this calibration curve. The calibration curve used for 
the conversion of the HU values thus has to be generated for each CT scanner using the 
same acquisition parameters (like the x-ray energy, the reconstruction filter and field of 
view) as the setting applied for the planning CT image acquisition (35). Any errors in the 
Calibration Curve are purely systematic and will affect the proton range in each treatment 
fraction to the same extent and consequently have a consistent effect on the delivered dose 
distribution. The errors in the Calibration Curve caused by inaccuracies in the process of 
converting the HU value into relative stopping power associated with this methodology has 
been found in general to be less than ± 1% (34, 35). Calibration Curve Errors are also 
caused by the uncertainty in the HU values themselves. The determination of the HU 
values is influenced of several factors; CT image noise, the Field of View during 
acquisition, the presence of CT artefacts like beam hardening, metal and motion artefacts 
and partial volume artefact due to density heterogeneities. Noise has been found to caused 
an error in the HU value of ±1% while the error in the HU values for bone and soft tissue 
is in the order of ±1,8% and ±1,1% respectively (34). A realistic and common used value 
for the estimation of the total CT based from HU to Relative Stopping Power conversion 
uncertainty is 3,5% of water equivalent range (36).   
 
 
2.4.2 Coordinate system and patient geometry.  
The patient geometry in radiotherapy is described by the three basic anatomical planes and 
by the patient coordinate system. In the patient coordinate system the x-axis runs from 
shoulder to shoulder, the z-axis from feet to head and the y- axis runs from front–back. 
The transversal body plane, also known as the cross-section or the axial plane, divides the 
body into cranial and caudal regions. The coronal plane, also called the frontal plane, 
divides the body into dorsal and ventral regions, and sagittal plane divides the body in left 
and right regions.  
 
Figure 2-11 displays the relations between the anatomical planes and the patient coordinate 
system on CT images. In Figure 2-11a) the CT image is displayed in the transversal view. 
The view is along the z-axis, the x-axis runs left -right and the y-axis dorsal - ventral. In 
Figure 2-11b) the CT image is displayed in the coronal view. The view is along the y-axis, 
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the x-axis runs left - right and the z-axis runs caudal-cranial. In Figure 2-11c) the CT image 
is displayed in the sagittal view. The view is along the x-axis, the y-axis runs dorsal - ventral 
and the z-axis runs caudal – cranial (37).  
 
 
 
 
 
 
Figure 2-11: The viewing planes in the patient including coordinate axis. In A) the transversal viewing plane is displayed, 
in B) the coronal plane is displayed and in C) the sagittal plane is displayed. Image from (37). 
 
 
2.4.3 Volume definitions 
The International Commission on Radiation Units & Measurements (ICRU) has developed 
standards for defining anatomic and geometric volumes, as well as nomenclature for dose-
volume specifications in radiation therapy (19). 
 
Figure 2-12 provides an illustration of anatomic and geometric volumes as defined by the 
ICRU: The Gross Tumour Volume (GTV) is the palpable, the visible or clinical 
demonstrable location and extent of the tumour. The Clinical Target Volume (CTV) is the 
tissue volume that contains the GTV and/or subclinical disease. The CTV is the volume 
we want to provide the prescribed dose. The Planning Target Volume (PTV) is a 
geometrical volume that contains the CTV with an additional uncertainty margin. The 
purpose of the uncertainty margin is to ensure that the prescribed dose is delivered to the 
CTV despite the different treatment variations. The Target volume (TV) is a general term 
associated with the tumour; it can either be the GTV, CTV or the PTV. Organs at risk 
(OAR) are normal tissue are organs whose radiation sensitivity can influence treatment 
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planning and/or prescribed dose. The volume of interest (VOI) is a generic term that can 
be used to refer to any volume that needs to be identified. Figure 2-14 gives a schematic 
illustration of the volumes and margins related to the definition of the target volume. 
 
 
 
 
Figure 2-12: Schematic illustration of anatomic and geometric volumes, as defined by the ICRU (19). 
 
 
 
 
In addition to the anatomic and geometric volumes described above, it is sometimes 
beneficial to define so-called Technical volumes that are needed in the planning process. 
These are for instance target volumes that are modified in the purpose of facilitating the 
optimization process. It can also be areas at the CT images that have to be assigned 
adjusted HU values. This could typically be in situations where CT artefacts influence the 
images and where the HU value would have to be changed to the average HU value of the 
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surrounding tissue, or in situations with the presence of external devices that are present 
during the CT image acquisition, but absent later, during the radiation treatment.  
 
 
 
 
2.4.4 Plan-and field specific parameters applied in passive scattering technique. 
In the passive scattering technique the concept of PTV is discarded and instead the field 
parameters are determined relative to the CTV.  The managing of uncertainties is solved by 
building the uncertainty margins in the field- and patient specific blocks and compensators 
(38).  
 
2.4.4.1  Apertures 
The purpose of apertures is to shape the lateral extent of the proton beam to the target 
volume and shield the surrounding healthy tissue. A block is normally made of brass and it 
is defined in the Beams-Eye-View (BEV) for each beam direction. The aperture is defined 
relative to the CTV by a distance corresponding to the internal target motion and the setup 
uncertainty. In addition it also includes the 95-50% penumbra with, determined at the 
widest extent of the target (39) (s 309).  
 
2.4.4.2  Distal  and proximal uncertainty margin 
The uncertainty in range due to potential errors in the calibration curve is handled by 
adding an extra distal and proximal margin to the CTV and thereby increases the SOBP. 
The distal and proximal margins are defined in order to account for a 3,5% uncertainty in 
the calibration curve and to account for beam range uncertainty due accelerator energy, 
variable scattering system thickness, compensator density amongst other (40). The distal 
margin, DM, is defined by the following equation: 
 𝐷𝑀!"# = 0,035  × 𝑑𝑖𝑠𝑡𝑎𝑙  𝐶𝑇𝑉  𝑑𝑒𝑝𝑡ℎ + 1− 3  𝑚𝑚   (Equation 2.10) 
 
The proximal margin, PM, on the CTV is calculated in the same way: 
 𝑃𝑀!"# = 0,035  × 𝑝𝑟𝑜𝑥𝑖𝑚𝑎𝑙  𝐶𝑇𝑉  𝑑𝑒𝑝𝑡ℎ + 1− 3  𝑚𝑚      (Equation 2.11) 
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2.4.4.3  The range compensator 
The range compensator conforms the distal end of the dose distribution to the target 
volume by varying thickness of a range-shifting material of water equivalent density. The 
thickness of the compensator is calculated by first to determine the Water Equivalent 
Thickness (WeT) to the target border for each so-called beamlet, which is a single energy 
beam positioned at a certain part of the target volume. The thickness of the compensator is 
then computed in terms of WeT differences by calculating the difference between the 
maximum WeT and the WeT at the border of the target volume. The range compensator 
has to be assigned a smearing margin in order to account for possible misalignment of the 
tissue density due to setup errors or organ motion. This smearing is performed by assigning 
each pixel in the compensator matrix with the minimum value from the vicinity pixels 
within a region defined by a user defined smearing margin (41).  
 
 
2.4.5 Plan- and field specific parameters applied in active scanning technique. 
In the following some plan- and field specific key parameters required for the optimization 
process and the calculation of the dose distribution are described.   
 
2.4.5.1  Lateral  and axial  margins 
The lateral and axial margins are defined relative to the target volume in each individual 
field (field specific margins). These so-called field specific margins are used in the initial 
beam and field calculation in order to define all possible spot positions for each particular 
field.  
 
The axial margin comprises a distal and a proximal margin. This means that for each field 
one adds a certain margin, for instance 2 mm, relative to the proximal and distal end of the 
target volume. During the calculation of the spot positions, the maximum and minimum 
energies for each field will be determined based on the depth of the proximal and distal 
end of the target volume in addition to the defined axial margins (37).  
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We have that similarly to the axial margins, a lateral margin is defined relative to the target 
volume for each field. Because of the discrete distance between the Bragg Peaks in the 
directions orthogonal to the beam direction (the spacing between the spots), there is a risk 
that the most superficial spots are positioned inside the target volume, which may result in 
problems achieving adequate dose coverage at the boundary of the target volume. By 
adding a lateral margin one ensures that spots also are positioned outside the target volume 
boundary when necessary (31, p. 341). 
 
 
2.4.5.2  Beam modi fy ing devi ces   
The depth of the Bragg Peak in matter is energy dependent, thus superficial target volumes 
require low proton energies, and for a target volume near, or at the body surface, the 
required energy will be lower than the minimum energy the Energy Selection System can 
provide. Target volumes that range from a very shallow depth to a very deep depth would 
require both low- and high-energy protons in order to be covered by a homogeneous dose 
at all levels. It is however difficult to produce protons with such a low energy from 
accelerators, which are designed to produce stable proton beams of energies of typically 
70-250 MeV. With synchrotrons there will be similar problems with producing protons 
with a requested energy below the energy range that the machine is designed for. Thus, the 
beam energy in some instances has to be degraded by introducing a pre-absorber in the 
beam, a so-called range shifter. The range shifter consists of a low Z material, normally 
water-equivalent material, this in order to minimize the beam divergence due to Multiple 
Scattering in the absorber material (31, p. 347).  
 
 
2.4.6 Optimization and calculation of the dose distributions 
2.4.6.1  Optimizat ion methods 
When applying the Single Field Optimization (SFO) technique each field is optimized 
independently to deliver a homogenous dose to the target volume. In a multifield treatment 
plan the dose distribution from each field are mutually weighted and combined by a simple 
addition. This technique is also referred to as Single Field Uniform Dose (SFUD) (42). No 
sparing of the OAR is possible with SFO beyond that achieved by a carefully selection of 
the field arrangements. 
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In the Multifield Optimization (MFO) technique all fields are optimized simultaneously 
and coupled together so that the target is coved with a homogenous dose when the 
contributions from each field are added together. Each field though, could have a 
heterogeneous dose distribution. The multifield optimization technique is also referred to 
as Intensity Modulated Proton Therapy (IMPT), and this technique allows for the sparing 
of the OAR during the optimization process. Several IMPT techniques exists, the most 
common and sophisticated is the 3D IMPT, in which all the Bragg peaks positioned 
throughout the target volume are individually weighted (43).  
 
2.4.6.2  Planning objec t ives  and objec t ive  funct ions 
The active scanning technique uses an inverse treatment planning approach. As briefly 
mentioned in chapter 2.2: the inverse approach implies the use of so-called planning 
objectives, which defines a set of treatment goals. The planning objectives, and their 
priorities, are mathematically formulated as objective functions. Typically these aims at 
minimizing the dose difference between the calculated dose distribution, and the defined 
objectives for the target volumes, OARs and other VOIs (organs at interest, normal tissue, 
technical volumes). It is a stepwise iterative process, which involves the spot weights being 
iteratively modified in order to achieve an optimal set of beam intensity distributions, so-
called fluence maps.  
 
The commonly used objective functions aims at either minimizing the volume of a VOI 
receiving a dose higher than a specified dose value, so-called upper objectives, or 
minimizing the volume of a VOI receiving a dose less than a specified, so-called lower 
objective. The upper objectives is typically expressed as; no more than V% can receive dose 
greater than D. Similarly the lower objective expresses that at least V% of the volume 
should receive dose greater than D. Upper and lower objectives are typically defined for 
the target volumes, while only upper objectives are defined for the organs at risk. Planning 
objectives for target volumes and organs at risk may be in direct conflict in a clinical 
situation, thus a weighted priority between the objective functions relative to their 
importance is required (28, 41). 
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2.4.6.3   The dose cal culat ion process  
The dose calculation process is a step-by-step process and in general, in a situation where 
one is applying the active treatment technique with spot scanning, it implies the steps in a 
process as the following:  
 
1. The first step includes the calculation of the initial spot list. This calculation is 
amongst other based on the defined target volume including the lateral and axial 
margins (see 2.4.4.1), the defined spacing between the energy layers, the defined 
spacing between the peaks and the size of the pencil beam.  
2. The second step involves the optimizing of the spot weights by the use of the 
defined objective functions.  
3. The final calculation includes firstly the calculation of the dose in each energy layer 
and secondly the summation of the dose contributions from all the pencil beams 
(beamlets) within each layer. In the final step of the calculation process doses from 
all layers are superimposed in order to calculate the overall 3D dose distribution 
(28, 41). 
 
 
2.4.7 Plan evaluation 
The evaluation of a treatment plan is based on analyzing and interpreting the calculated 
dose distribution both qualitatively and quantitatively. The qualitatively evaluation is done 
by displaying the dose distribution on the planning CT images and analyze this, slice by 
slice, and in each of the anatomical planes. The quantitatively evaluation is done by 
interpreting Dose Volume Histograms and by the calculation of quantitative indices which 
quantifies the homogeneity and conformity of the treatment plan.  
 
 
2.4.7.1  Visual izat ion o f  the dose dis tr ibut ion 
Dose distributions are commonly displayed on the CT images by isodose curves or by so 
called colour wash as illustrated in Figure 2-13a) and Figure 2-13b). Isodose lines are a set 
of closed contours that are passing through voxels or points of equal dose. All voxels 
enclosed by the contour have doses equal to, or above the specific dose level defined by 
the contour. They can be expressed either as absolute dose levels, of as percentage of the 
prescribed dose. They are usually defined in regular intervals as shown in Figure 2-13a)).  
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Colourwash displays dose distribution in a continuous colour map (Figure 2-13b)). The 
dose levels are scaled by a colour bar. The range of dose levels is user defined; one can 
show all the dose values, or limit the visualization. Doses that exceed a range limit are 
showed in some chosen colour, dose below the range is not visualized. As for the isodose 
curves, the colourwash can be displayed in both absolute and relative units of the 
prescribed dose (37).  
 
 
 
 
Figure 2-13: In image 2-13a) the dose distribution is displayed by isodose lines, ranging from the 50% level to the 110 % 
level. Each dose level is assigned a colour as displayed to the left in the image. In image 2-13b) the dose distribution is 
displayed by colour wash, from the 50% dose level to the 107% dose level. The dose levels are displayed by the colour 
bar scale to the left in the image. Doses below the defined colour range are not visualized. 
 
 
2.4.7.2  Dose and Dose-Volume Histogram re lated de f ini t ions 
A Dose Volume Histogram (DVH) graphically summarizes the dose distribution within a 
volume of interest. Dose-volume specifications can be directly read from the DVH and is, 
together with visualization of the dose distribution, an important tool in evaluating 
treatment plans. Figure 2-14 gives an overview over different dose-volume specifications 
that can be read out of the DHV.  
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Figure 2-14: Dose Volume Histogram (DVH). Both dose and volumes can be in relative or absolute units. The structure 
volume is displayed on the y-axis and dose on the x-axis. The figure is illustrating typical dose-volume relations that are 
read out of the DVH (19). 
 
 
 
The DV is the least dose received by a volume V, of a specified VOI. To exemplify; D80% = 
70 Gy(RBE) means that at least 70 Gy(RBE) is delivered to 80 % of the volume.  For both 
cases the volume V and the dose D can be reported in absolute or relative units.  
 
The quantity VD is the largest volume of a specified VOI that receives at least a specified 
dose. To clarify; the expression V34,3Gy = 95% would mean that 95% of the volume receives 
at least 34,2 Gy(RBE).   
 
The Dmin = D100% and is the minimum dose delivered to a voxel within a VOI, usually the 
target volume. The Dmax=D0% and is the maximum dose delivered to a voxel within a VOI, 
usually the target volume.  
 
The D98% is also denoted as the Dnear-minimum and quantifies the dose level received by at 
least 98% of a VOI, usually the target volume. Consequently 2% of the volume receives 
doses below this level.  
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Similarly the D2% also denoted as the Dnear-maximum, quantifies the least dose received by 2% 
of target volume and accordingly it will be 2% of the VOI, which receives dose above this 
level. The D98% and D2% value is not as sensitive as the Dmin and Dmax with the respect to 
the dose calculation matrix resolution, and also with respect to variability in contouring, 
patient anatomy, which a very significant factor, and also to patient movement, and is 
therefore taken as a more applicable and clinical relevant parameter.  
 
The Dmeanis the mean or average dose delivered to a VOI. The D50% is termed the median 
dose delivered to a VOI. The value of Dmean will for a target volume normally be close to 
the median dose as opposed to the situation for the mean dose to an OAR (19) .    
 
 
2.4.7.3  Indices  used to descr ibe and evaluate  treatment plans  
To further describe dose distribution and the quality of a treatment plan, a number of 
indices are often used.  
 
The Conformity Index (CI) is used to quantify how well the prescribed dose is 
conformed to the CTV or PTV. The CI is defined as the ratio of the treated volume to the 
PTV or CTV:  
 𝐶𝐼 = !"!"!"         (Equation 2.11)
  
 
In this equation, TVRI is the target volume covered by the reference isodose, and TV is the 
target volume (44). The reference isodose is 95% of prescribed dose. The index ranges 
from 0 (the entire target is situated outside the prescription dose or reference isodose) to 1 
(all of the target volume is irradiated to the prescription dose or reference isodose). This 
index does not take into account the volume of adjacent healthy tissue.  
 
The Conformity Number (CN) takes into account both the irradiated target volume and 
healthy tissue. The CN is defined as 
 𝐶𝑁 = !"!"!" × !"!"!!"         (Equation 2.12) 
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where TVRI is the target volume covered by the reference isodose, TV is the target volume 
and VRI is the total volume of the reference isodose (44). The reference isodose is 95% of 
prescribed dose. A CN of 1 is ideal.  
 
The Homogeneity Index (HI) is used to quantify dosimetric homogeneity within the 
CTV or PTV. The HI is defined as 
 𝐻𝐼 = !!%!!!"%!!"%         (Equation 2.13) 
 
where D2% is the dose delivered to the 2% of the TV that receives the highest dose, and 
D98% is minimum dose received by 98 % of the TV, D50% is the median dose to the TV (45). 
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3 STUDY DESIGN 
The treatment plans and dose calculations in this study were all generated in the Eclipse™ 
treatment planning system (Varian Medical Systems, Palo Alto, CA, USA) for proton 
therapy, including the dose calculations after the simulation of tissue density changes, 
geometric errors and range estimation errors. The Brilliance Big Bore CT scanner (Phillips 
Healthcare, Best, Netherlands) was used in acquisition of the CT images used for creating 
the craniospinal treatment plans.  
 
3.1 The water phantom study 
3.1.1 Design of the homogeneous and heterogeneous phantoms  
The first part of this study included the construction of cubic water phantoms in the 
treatment planning system. Three different phantoms were manually designed in the 
treatment planning system, all with the outer dimensions of 30 x 30 x 30 cm3. The 
treatment planning software enables the user to assign a HU value in any defined volume 
inside of the dose calculating area; the HU value was thus set to 0 in order to set the 
density to water in all the phantoms. Figure 3-1 displays the phantoms.  
 
Phantom Awater consisted of the outer 30 x 30 x 30 cm
3 water volume surrounding a cube 
shaped target volume with the dimension 10 x 10 x 10 cm3. The target volume was placed 
at the centre of the phantom and consisted of water (assigned a HU value of 0). Thus 
phantom Awater was a completely homogenous water phantom.  
 
Phantom Bbone consisted of the outer 30 x 30 x 30 cm
3 water volume surrounding a cube 
shaped target volume with the dimension 10 x 10 x 10 cm3 and with an additional cubic 
inner structure of 5 x 5 x 5 cm3. The inner structure of the target volume consisted of bone 
(assigned a HU value 1000), the rest of the target volume consisted of water (assigned a 
HU value of 0). Thus the target volume in Phantom Bbone was heterogeneous consisting of 
a composition of bone and water.  
 
Phantom Cair consisted of the outer 30 x 30 x 30 cm
3 water volume with a cube shaped 
target volume with the dimension 10 x 10 x 10 cm3 and with an additional cubic inner 
structure of 5 x 5 x 5 cm3. The inner structure of the target volume consisted of air 
(assigned a HU value -1000), the rest of the target volume consisted of water (assigned a 
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HU value of 0). Thus the target volume in Phantom Cair was heterogeneous consisting of a 
composition of air and water.  
 
 
 
 
 
Figure 3-1: The phantoms: The red cubes at the centre of the water phantoms illustrate the target volumes. Phantom 
Awater: The target volume is completely homogeneous consisting of water.  Phantom Bbone: the target volume is 
heterogeneous consisting of bone (white inner structure) and water. Phantom Cair: the target volume is heterogeneous 
consisting of air (blue inner structure) and water. All target volumes are placed at the centre of the water phantoms.  
 
 
3.1.2 The water phantom reference plans 
The water phantom reference plans were created in order to represent the “ideal” situation 
with no errors applied. The proton dose distributions in the water phantoms were 
generated applying a one-field plan on each of the phantoms; Awater, Bbone and Cair. A lateral 
field specific margin of 1 cm relative to the target volume was applied. The proximal and 
distal field specific margins were set to 0. The isocenter was positioned at the centre of the 
target volume. The dose distributions were generated using the active scanning technique, 
with a single field optimization (SFO) option. The total dose of 10 Gy was prescribed.  
The dose-volume objectives used for optimization were:  
1. Lower objective: 100% of the target volume should receive at least 9,8 Gy.   
2. Upper objective: 0 % of the target volume should receive more than 10,2 Gy.  
3. The maximum number of iteration was set to 1000.  
For all the plans, the optimizing process completed prior to reaching the maximum 
number of iterations. After optimizing the plans according to the dose-volume objectives 
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described above, the plans were calculated and normalized so that the 95% dose covered 
100% of the target volume. The total dose distributions for the reference plans, which were 
used as reference for the error simulations, are displayed with isodose lines in the top panel 
of Figure 3-2, and with the 95% -107% dose distribution displayed in colour wash in the 
bottom panels of Figure 3-2. The corresponding dose statistics are listed in Table 3-I. 
 
 
 
Figure 3-2: The total dose distributions are displayed by isodose lines in the top panel for phantom Awater, Bbone and Cair. 
The corresponding 95%-107% dose distribution is displayed in colour wash in the bottom panels. Phantom Awater is 
showed on the left, phantom Bbone in the middle and phantom Cair on the right. The black arrow in the images indicates 
the beam direction. 
 
Table 3-I: Dose statistics, displayed in relative values (%), for the reference plans on phantom Awater, Bbone and Cair. 
              
Parameter Dmin Dmax V95% Dmean D98% D2% 
Awater 95,0 103,5 100,0 101,1 102,6 98,9 
Bbone 95,0 104,4 100,0 101,3 102,4 99,7 
Cair 95,0 108,6 100,0 102,3 104,5 100,2 
 Abbreviations: Dmin = D100%: minimum dose delivered to the target volume. Dmax=D0%: maximum dose delivered to the 
target volume. V95%: Volume receiving at least 95% of prescribed dose. Dmean: mean/average dose delivered to the target 
volume. D98% = Dnear-minimum: least dose received by 98% of the target volume. D2%= Dnear-maximum: least dose received by 
2% of the target volume. 
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3.1.3 Simulation of changes in tissue composition in the beam path 
The simulation of a change in the tissue density in the beam path was performed in the 
treatment planning system in the following way:  
 
• Rectangular volumes with varying thicknesses of 0,5 cm, 1,0 cm, 1,5 cm, 2,0 cm 
and 2,5 cm were designed. 
• The rectangular volumes were assigned a HU value of 1000, representing bone, and 
a HU value of  -1000, representing air.  
• The air and bone volumes were sequentially inserted in the beam path 1 cm and 5 
cm in front of the target volume, covering the entire target volume area in the 
beam’s eye view (Figure 3-3).  
• So-called verification plans based on the reference plan designed in phantom Awater 
were then recalculated with water being sequentially replaced by the air and bone 
volumes.  
 
By using verification plans for this purpose, the recalculation of the dose distribution could 
be performed using the initial spot distribution from the reference plan (the spot 
distribution with no air or bone volumes). By using this procedure instead of performing a 
new recalculation of the dose distribution, the effects of the density changes could be 
obtained and their consequences manifested in the recalculated so-called error dose 
distributions.  
 
The effect of the density changes on the proton range (ΔR), the distal dose fall-off, as well 
as the Dmin and V95% to the target volume was investigated by analysing and comparing the 
depth dose profiles and the cumulative DVHs from the reference plans and the 
recalculated verification plans. To represent the proton range, the position in depth of the 
distal 90% dose level on the central beam axis dose profile (d90%), was chosen. The distal 
dose fall-off was defined as the distance between the distal positions in depth of the 80% 
and20% dose levels (d80%-d20%) as illustrated in Figure 3-4. The definitions of the 
parameters are based on the definitions given by Gall et al and cited in (19). 
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Figure 3-3: Examples showing the air and bone volumes with different thicknesses and their positions relative to the 
target volume (drawn in solid red line). The figure is in transversal view and shows the 0,5 cm thick bone volume (I) and 
the 2,0 cm thick air volume (II) placed 1 cm in front of the target volume, further the 1,5 cm thick bone volume (III) and 
the 1,0 cm air thick volume (IV) positioned 5 cm in front of the target volume. The black arrow indicates the beam 
direction. 
 
 
 
 
Figure 3-4: The definitions of the range (d90%) and the distal dose fall-off (d80%-d20%). The range is defined as the 
depth of the distal 90% dose level on the central axis dose profile. The distal dose fall-off as the distance between the 
distal depths of the 80% and 20% dose levels (d80%-d20%). 
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3.1.4 Simulation of geometric errors 
The simulation of geometric errors was performed in the treatment planning system in the 
following way:  
 
• Verification plans, based on the reference plans in phantom Awater, Bbone and Cair, 
were created and used for systematically shifting of the isocenter in one direction at 
the time. 
• The magnitude of the isocenter shifts were of ±5 mm and the shifts were 
performed along the x-, y- and z –axis, as illustrated in Figure 3-5.   
• The verification plans from phantom Awater, Bbone and Cair were then recalculated, 
now with the target volume misaligned relative to the beam due to the isocenter 
shifts. The recalculation was performed using the initial spot distribution (the spot 
distribution with no isocenter shifts) from the reference plans. 
  
 
Figure 3-5 illustrates the shift directions relative to the direction of the proton beam. As 
the figure illustrates; shifts in the lateral direction are along the x-axis, shifts in the 
longitudinal direction are along the z-axis and shifts in the vertical direction are along the y-
axis, this is in the beam direction. The lateral and longitudinal isocenter shifts were 
perpendicular to the beam axis (marked with the yellow arrow in the figure), while the 
vertical isocenter shifts were parallel to the beam axis. 
 
The procedure described above resulted in 6 recalculated dose distributions. The variables 
investigated were the Dmin, Dmax, V95% and the HI.  The resulting dose distributions and 
dose profiles were also evaluated.  
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Figure 3-5: The coordinate system and the axis definitions: The figure displays the relations between the 3 axes in the 
coordinate system used in this study and the proton beam direction. The beam direction, which entered the phantom 
from above as indicated by the yellow arrow in the figure, was similar in all plans. 
 
 
 
3.2 Robustness analysis of craniospinal treatment plans 
The treatment planning method used in creating the craniospinal treatment plans, was 
based on the guidelines for conventional CS planning at Haukeland University Hospital 
(HUH) (46), the reference manual from the treatment planning system (37, 41) and 
published papers by (7, 47-49).  
 
3.2.1 The CT image datasets for treatment planning 
Anonymous CT image dataset from 6 paediatric patients who earlier had been treated at 
HUH were included in this study. The image datasets consisted of a set of predefined 
structures, as well as the dose distributions belonging to the treatment plans that were 
delivered in the already executed radiation treatment of the patients. The patients had all 
been immobilized in prone position in a vacuumed cushion filled with tiny polystyrene 
beads fix (Vac-Lock™ from Civco Medical Solutions, Orange City, USA) and a 
thermoplastic mask (Posicast® from Civco Medical Solutions, Orange City, USA) The 
patient positioning and fixation was according to HUH procedures for conventional 
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craniospinal treatments. The patient volume from top of the head to lower sacrum was 
included in the CT scans, which were performed with a slice thickness of 3 mm.  
 
 
3.2.2 The definition of target volumes and organs at risk 
In the radiotherapy treatment of CNS tumours where there is risk of seeding into to the 
cerebrospinal fluid with subsequent metastasizing, the primary target volume consists of 
the whole brain and the spinalcanal, through the cauda equina to the junction area between 
the second and third sacral vertebrae (S2/S3). In the predefined structure sets, no CTV had 
been delineated. However, the brain and the spinal canal were defined, these volumes were 
reviewed, and modified, if necessary, according to the criteria mentioned above, after 
which the CTV was created by a Boolean summation operation of the two volumes. The 
CTV was then extended to also include the entire corpus vertebrae. This is a common 
approach in proton craniospinal treatments for paediatric patients in order to avoid that the 
steep dose gradients result in non-uniform irradiation of the corpus vertebra, with the 
possibility of asymmetric growth of the skeleton as a consequence (50). 
 
An asymmetric uncertainty margin was added to the CTV in order to create the PTV. The 
CTV was expanded with 4 mm in all directions in the brain area as displayed in Figure 3-
6a) and 5 mm in the lateral and proximal direction in the area of the spinal canal. No 
margin was added distally, thus the CTV and the PTV coincide along the edge of the 
corpus vertebrae as displayed in Figure 3-6b) and Figure 3-6c). The choice of using no 
margins around the vertebral area is based on the fact the primary target volumes in the 
treatment regimen are the brain and the spinal canal. The inclusion of the corpus vertebra 
in the CTV volume only serves the purpose of avoiding radiation-induced growth 
disorders, but this with the consequence of an increased irradiated volume. It was therefore 
desirable to keep the volume of CTV as small as possible. The idea being, that a target miss 
in this area could only, in the worst-case, lead to asymmetric growth, and not affect the 
clinical outcome (i.e. the prognosis for survival).   
 
For optimization purposes the PTV was divided into a cranial PTV (PTVcran), which 
included the brain and most of the cervical spine, and a spinal PTV (PTVspin), which 
included the whole spinal canal. The PTVcran and the PTVspin were overlapping to avoid an 
edge-to-edge junction between the volumes (Figure 3-6d)). The choice of dividing the PTV 
 48 
into two separate volumes was due to the different sizes of the PTV in the brain and spinal 
area. The idea was that it would ease the optimization process when the PTV was divided 
into two different volumes, volumes that in turn were allocated similar dose-volume 
objectives (47).   
 
A Normal Tissue volume was also defined. The intention of this volume was, by assigning 
it with upper dose-volume objectives during the optimization process, to reduce the dose 
to the surrounding healthy tissue. The Normal Tissue enclosed the PTV by 3 cm and it was 
outwardly constrained by the body surface. An inner margin between the Normal Tissue 
and the PTV of 3 mm was applied; this to avoid a conflict between the dose volume 
objectives assigned the PTV and the Normal Tissue during the optimization process. 
 
The organs at risk delineated in this study were the lenses, the eyes, the thyroid, the heart, 
the lungs and the kidneys. Table 3-II gives an overview over the individual volume sizes (in 
units of cm3) of treatment planning volumes for all the 6 patients. Descriptive statistics is 
included in the table with the values for the mean, standard deviations, median, maximum 
and minimum.  
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Figure 3-6: The defined target volumes in the craniospinal treatment plans. The CTV and PTV are shown in a) in the 
cranial area and in b) in the spinal area in in transversal plane, with the similar volumes showed in c) in the sagittal plane. 
In d) the PTVcran is showed in magenta, while the PTVspin is showed in cyan. 
 
 
 
 
Table 3-II: The treatment planning volumes defined in craniospinal treatment plans (in units of cm3) for patient I-VI. The 
descriptive dose statistics is also displayed including the mean, the standard deviation, the median, the minimum and the 
maximum values. 
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  Treatment planning volumes (cm3) 
Patient  PTV CTV Heart Left lung 
Right 
lung 
Left 
kidney 
Right 
kidney 
Left 
eye 
Right 
eye Brain 
Spinal 
canal Thyriod 
I 2308,0 1912 246,4 550,5 653,8 99,0 101,3 10,6 10,8 1440,1 114,1 3,3 
II 2387,0 1975 204,1 417,2 500,5 81,3 91,0 7,0 11,2 1587,2 96,4 5,3 
III 2102,0 1756 180,2 433,7 523,5 71,6 60,1 8,4 6,9 1379,7 71,3 2,7 
IV 1996,0 1672 222,8 537,0 626,5 70,4 63,1 7,7 7,6 1344,8 76,0 3,8 
V 2114,0 1849 167,4 235,7 253,1 47,6 49,0 7,6 8,4 1590,0 64,5 2,5 
VI 2015,0 1670 180,1 224,9 333,0 68,5 64,5 7,8 7,8 1326,9 105,1 1,6 
Mean 2153,7 1805,7 200,2 399,8 481,7 73,1 71,5 8,2 8,8 1444,8 87,9 3,2 
SD 159,1 127,0 30,1 141,8 159,4 16,8 20,1 1,3 1,8 117,9 20,1 1,3 
Median 2108,0 1802,5 192,2 425,5 512,0 71,0 63,8 7,8 8,1 1409,9 86,2 3,0 
Min 1996,0 1670,0 167,4 224,9 253,1 47,6 49,0 7,0 6,9 1326,9 64,5 1,6 
Max 2387,0 1975,0 246,4 550,5 653,8 99,0 101,3 10,6 11,2 1590,0 114,1 5,3 
Abbreviations: SD= standard deviation, Min= minimum, Max=maximum.  
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3.2.3 The design of the treatment fields in the craniospinal treatment plans 
The treatment plans were made under the assumption that the treatment could be 
performed with a rotating gantry and hence with the possibility to design treatment plans 
with multiple beam angles. All the plans had similar beam arrangement. Most of the spinal 
canal was covered by 2 posterior fields, both with beam angles of 0° (upper and lower 
spinal fields). The brain and the cranial part of the spinal canal were covered by 2 lateral 
oblique fields, which were angled 15° from the horizontal axis, i.e. with the beam angles of 
75° and 285° (cranial fields). The choice of using angular cranial fields was based on the 
result from the study of Cochran et al, which showed considerable sparing of the doses to 
the lens by angling the fields 15°-20° to the posterior (48). The isocenter in each field were 
placed at the same lateral and vertical level, requiring only longitudinal shifts between the 
fields. The distance between each isocenter was 15- 20 cm causing an overlap between each 
field in order to achieve treatment plans less sensitive to setup errors in the junction area 
(47).  
 
Field specific margins were added in all fields. The lateral margin was 1 cm for all fields.  
For the cranial fields, no proximal margin was added. The distal margin was set to 0,3 cm 
relative to the PTVcran. For the spinal fields, the proximal margin was set to 0,1 cm and the 
distal margin to 0,2 cm, both relative to the PTVspin. The margin sizes were determined 
based on the proximal and distal water equivalent distance (WED), as measured on the CT 
images at the isocenter level. The distal margin were calculated by: 
 
DM=DWED x 3,5%       (Equation 3.1) 
 
Here the DM is the distal margin and the DWED is the water equivalent range to the distal 
part of the PTV. Similarly the proximal margin were calculated by: 
 
PM=PWED x 3,5%       (Equation 3.2) 
 
Here the PM is the proximal margin and the PWED is the water equivalent range to the 
proximal part of the PTV. 
The available beam energies in the treatment planning system ranged from 70 MeV to 250 
MeV. Because the target volumes here were close to the body surface, energies less than 70 
MeV was required for spots to be delivered at a shallow enough depth to obtain proximal 
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target coverage. A range shifter of 57 mm thickness and consisting of water equivalent 
material was applied in order to adjust the overall proton range and by this to ensure the 
proximal target coverage. Table 3-III lists the beam specific parameters. 
 
 
 
 
 
 
Table 3-III: The beam specific properties defined by the user during the planning process of the craniospinal treatment 
plans.  
Field 
number 
Gantry 
angle 
Lateral 
margin 
Proximal 
margin 
Distal 
margin Target  
Range 
shifter 
1 75° 1,0 cm 0,0 cm 0,3 cm PTVcran Yes 
2 285° 1,0 cm 0,0 cm 0,3 cm PTVcran Yes 
3 180° 1,0 cm 0,1 cm 0,2 cm PTVspin Yes 
4 180° 1,0 cm 0,1 cm 0,2 cm PTVspin Yes 
 
 
 
3.2.4 Optimizing and calculating the treatment plans 
The prescribed dose was 1.8 Gy (RBE) in 20 fractions adding up to a total dose of 36 Gy 
(RBE). The plans were optimized using the Multifield Optimization technique. The plans 
were designed using upper and lower dose-volume objectives for the PTVcran and PTVspin, 
as well as upper objectives for the OAR. In Table 3-IV the dose-volume objectives for all 
volumes are listed, the listed objectives were used as a starting point for the optimization 
process, thus during the optimizing process the objectives were modified more ambitious 
when possible and less ambitious if necessary. The modifications were performed by 
changing the priority or the dose volume objectives for the OAR without compromising 
the PTV objectives, or by changing the priority for the upper or lower dose-volume 
objectives for the PTVs in order to meet the dose constraints. 
 
The scanning spot spacing and the spacing between the energy layers were defined to be 
0,5 cm respectively, and the number of iterations was set to 2000. The optimizing process 
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continued until the maximum number of iterations was reached. The treatment plans were 
calculated with a proton pencil beam algorithm and the dose in each plan was normalized 
to the median: a 100% of the prescribed dose to be given to 50% of the PTV. 
 
 
 
 
 
Table 3-IV: The dose volume objectives used as starting point in the optimizing process. The PTV is divided into two 
separate volumes (PTVspin and PTVcran), each assigned identical dose volume objectives. 
	  	   	  	   	  	   	  	   	  	  
Organ Limit Volume [%] Total Dose [Gy] Priority 
PTVspin Upper 0,0 36,5 120 
  Lower 100,0 35,5 120 
PTVcran Upper 0,0 36,5 120 
  Lower 100,0 35,5 120 
Eyes Upper 2,0 35,5 50 
Heart Upper 0,0 12,5 50 
  Upper 5,0 5,0 50 
Kidney Upper 2,0 20,0 50 
  Upper 8,0 10,0 50 
Lens Upper 0,0 5,0 50 
Lung Upper 3,5 20,0 50 
  Upper 12,0 10,0 50 
Normal Tissue Upper 0,0 36,0 50 
 Upper 15,0 30,0 50 
 
Upper 40,00 20,0 50 
  Upper 60,00 6,0 50 
 
 
 
 
3.2.5 Evaluation of the craniospinal treatment plans 
The treatment plans were evaluated both qualitatively and in terms of quantitative criteria 
based on common recommendations for radiation therapy (45, 51). In a clinical situation, 
the evaluation of a treatment plans is sometimes a trade-off between the goal of adequate 
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target coverage and the OAR dose constraints. In this study the main goal was to achieve 
sufficient target coverage, no compromises was made with respect to the target coverage.  
 
The plans were evaluated qualitatively by visually analysing the dose distribution. The plans 
were evaluated slice by slice, with respect to both the total dose distribution and the 95%-
107% dose distribution. The 95% dose should cover the PTV with no large hotspots 
(doses >107% of prescribed dose) in normal organs or large cold spots in the target 
volume (doses < 95% of prescribed dose). Quantitatively the plans were evaluated in terms 
of: 
 
• PTV D98% ≥ 95% of prescribed dose,  
• PTV D2% ≤ 107% of prescribed dose, 
• PTV V95% = 100%. The 95% corresponds to 34,2 Gy (RBE). 
 
The HI, the CI and the CN were also calculated for the PTV. In addition the PTV Dmax 
and the PTV Dmin were too evaluated.  
 
3.2.6 Simulation of range- and geometric errors in craniospinal treatment plans 
Two different scenarios were studied. The first situation to be investigated was the effect 
of errors in the estimated proton range in the patient, due to uncertainties in the patient’s 
density map, as this was calculated based on the planning CT. These errors are denoted as 
the Calibration Curve Errors (CCEs). Secondly, the effects of geometric errors due to 
deviations between patient position at planning and during the patient position during 
treatment delivery – these errors are denoted setup errors. The simulations of both the 
range- and geometric errors are based on the methods described by Lomax (13, 14).  
 
3.2.6.1  Calibrat ion Curve Errors (CCE) 
The CT calibration curve converts the HU values into relative proton stopping power as 
discussed in chapter 2.4.1. To simulate a range error due to uncertainties in the calibration 
curve, the reference dose distribution were recalculated with a systematically change in the 
calibration curve of -1% to -5 %, causing a so-called overshoot, or with a systematically 
change in the calibration curve of +1% to +5 %, causing a so-called undershoot. By 
imposing an error into the calibration curve with a positive specified value, the relative 
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stopping power increases by that specified amount and consequently the proton range 
decreases relative to the reference plan (undershoot), thus moving the Bragg Peak closer to 
the source. Similarly, if the applied error had a negative value, the stopping power value 
decreased and the proton range was prolonged (overshoot), thus moving the Bragg Peak 
further away from the source.  
 
In the treatment planning system this procedure is implemented in the Range Uncertainty 
tool. The purpose of the Range Uncertainty tool is to estimate the sensitivity of the 
treatment plans with respect to range- and geometric uncertainties. This is done by 
generating a set of recalculated dose distributions - so-called error distributions-based on 
the reference plans. The user manually defines the magnitude of the calibration curve 
errors and the dose distributions are recalculated with the initial spot distribution, resulting 
in a new dose distribution for each uncertainty parameter defined, where the effects of the 
errors are manifested (37).  
 
3.2.6.2  The s imulat ion o f  se tup errors  
The simulation of a set up errors can be obtained by shifting the patients CT dataset 
relative to the isocenter, this followed by a recalculation of the dose distribution on the 
shifted versions of the patients 3D CT datasets. Typically this is done in the treatment 
planning system by shifting the isocenter of the treatment plan along the x-, y- and z-axis. 
The Range Uncertainty tool in the treatment planning system was also used for the 
simulation of the setup errors. The isocenter was shifted along the x-, y- and z-axis in the 
range from 1-5 mm in 1 mm steps. In Figure 3-7, the directions of the shifts relative to the 
patient are illustrated. Patients were positioned in the prone position, thus a negative lateral 
shift moved the isocenter in the left direction, while a positive shift moved the isocenter in 
the right direction. A negative shift in vertical direction moved the isocenter dorsally, and a 
positive shift moved the isocenter ventrally. Finally, a negative longitudinal shift moved the 
isocenter in the caudal direction, while a positive longitudinal shift moved the isocenter in 
the cranial direction. The following recalculation resulted in 30 spatially shifted dose 
distributions, one for each shift.  
 
 
 
 
 55 
 
Figure 3-7: The figure shows the directions of the isocenter shift in a patient in a “head first –prone” position. The shifts 
in the left (-) and the right (+) directions are along the x-axis, the shifts in dorsal (-) and ventral (+) are along the y-axis, 
and the shifts in caudal (-) and cranial directions are along the z-axis.   
 
 
 
3.2.7 Analysis of the results 
The error dose distributions were compared to the reference dose distributions by means 
of an evaluation of the DVHs, by studying and analysing the 2D visualization of the 
individual error doses dose distributions and by evaluating the Max-Min dose distribution. 
The DVHs resulting from the use of the Range Uncertainty tool (the reference DVH 
including the uncertainty curves) could not be exported. Thus, the DVHs were manually 
analysed in the treatment planning system by observing the dose-volume statistics from 
each DVH. The individual error doses could be displayed both in colour wash and by 
isodose curves in the transversal, sagittal and coronal plan with the dose statistics, such as 
the 3D dose maximum, the 3D dose minimum, the 3D dose maximum and the 3D mean 
dose for the target volume also displayed. The Max-Min function is implemented as a part 
of the Range Uncertainty tool. The Max-Min dose distribution tool visualised in what areas 
in the patient the largest difference in dose occurred. The Max-Min dose is a point-wise 
calculated dose difference, this based on the initial dose and all the uncertainty doses, and it 
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shows how robust a plan is with respect to the user defined range- and setup errors. The 
Max-Min dose distribution is calculated by:  
 𝐷!"#!!"# 𝑥 = 𝐷!"# 𝑥 − 𝐷!"# 𝑥      (Equation 3.3) 
 
The 𝐷!"# 𝑥  is the maximum dose of all calculated doses, including the initial dose, at a 
point x. Similarly, the 𝐷!"# 𝑥  is the minimum dose of all the calculated doses at the same 
point x (37). The result is displayed in colour wash mode ranged from blue to red, with 
blue representing small or no difference between the maximum and minimum doses, and 
with red showing the biggest difference between the maximum and minimum doses.  
 
Several quantitative variables were studied when comparing the reference dose distribution 
and the error dose distributions. As the endpoint for quantifying what impact the induced 
range- and geometric errors had on the doses to the target volume, the V 34,2Gy (RBE) for the 
CTV was chosen (this representing the volume receiving the 95% of the prescribed dose). 
The brain and spinal canal were also evaluated with respect to the V 34,2Gy (RBE).  
 
As the primary endpoint for quantifying what impact range- and geometric errors had on 
the doses to OAR, the Dmean and V5Gy was chosen.  
 
Results will be presented both for the individual patients and at the patient group level. 
Descriptive statistics in terms of the median, the mean with standard deviations (SD), 
range, maximum and minimum values will be presented both in tables and in figures. The 
data will also be presented graphically, by DVHs, by dose profiles and with screenshots 
from the treatment planning system. 
 
3.2.8 Ethical considerations 
No patients were involved in this study. Anonymous 3D CT image datasets, from the 
database in the treatment planning system, were used for the treatment planning of the 
craniospinal treatment plans.  
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4 RESULTS 
4.1 Water phantom study 
In this section the results from the water phantom study are presented. The results from 
the simulations of changes in the tissue composition in the beam path are given in 4.1.1 
and the results from the simulations of geometric misalignments are presented in 4.1.2.   
 
4.1.1 Effects of changes in tissue composition in the beam path  
Figure 4-1 and Figure 4-2 displays the depth dose profiles along the central beam axis for 
the reference proton plan, and the corresponding depth dose profiles from the proton 
plans that have been recalculated after inserting volumes of bone (Figure 4-1) and volumes 
of air (Figure 4-2) in the beam path at two different depths. The 2,5 cm thick bone- and air 
volumes are positioned at a 6,5 cm depth, which is 1 cm prior to the target volume, and at 
2,5 cm depth, which is 5 cm prior to the target volume.  
 
These results demonstrate how a shift in the depth dose distribution occurs when changing 
the material density relative to the calculated reference distribution. At the distal end of the 
dose profile, the starting point of the rapid dose fall-off is shifted to a shallower depth after 
traversing the bone volume. The opposite effect is observed by introducing the air volume 
in the beam path. This will shift the starting point of the dose fall-off to a greater depth 
compared to the situation in homogenous water. The depth in which the volumes were 
inserted had little influence on the observed effect at the end of the SOBP, demonstrated 
by the curves that coincide very well both distally and over the whole SOBP plateau.  
 
In the entrance region however, the dose profiles are different depending on depth of the 
inserted volumes. In the situation where the bone volume was introduced at the depth of 
2,5 cm, a more rapid increase in depth dose occurred, compared to the situation were the 
bone volume were inserted at 6,5 cm depth. The opposite effect was seen following the 
introduction of the air volumes at the same positions in depth; the air volume positioned at 
2,5 cm resulted in a slower increase in depth dose compared to the air volume located at 
6,5 cm depth.  
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Figure 4-1: The depth dose profiles at the central axis of the phantom after inserting a 2,5 cm thick structure volume of 
bone at 2,5 cm (solid red line) and 6,5 cm (dashed green line) depth. The solid black line represents the reference depth 
dose profile. The red shaded and green shaded areas indicate where the beam reach the inserted volume at 2,5 cm and 6,5 
cm depth, respectively.  
 
 
 
 
 
 
Figure 4-2: The depth dose profiles at the central axis of the phantom after inserting a 2,5 cm thick structure volume of 
air at 2,5 cm (solid red line) and 6,5 cm (dashed green line) depth. The solid black line represents the reference depth dose 
profile. The red shaded and green shaded areas indicate where the beam reach the inserted volume at 2,5 cm and 6,5 cm 
depth, respectively. 
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The Table 4-I lists the resulting proton range (d90%) and the distal dose fall-off (d80%-
d20%) after the insertion of bone and air volumes of different thickness. The table lists the 
results for the bone and air volumes inserted 1 cm prior to the target volume, but equal 
results were found when the volumes were inserted 5 cm prior to the target volume.   
 
The range changed as a function of the varying thickness of the inserted bone and air 
volumes. In the reference dose distribution, with no air or bone volumes inserted, the 
range was 20,3 cm. The consequence of introducing bone in the proton beam was a 
continuous reduction in range from 20,0 cm to 19,2 cm, dependent on the thickness of the 
bone-volumes (from 0,5 cm to 2,5 cm). The opposite effect was seen following the 
insertion of the air-volumes of the same thickness, a gradual increase in beam penetration 
that ranged from 20,7 cm with 0,5 cm air to 22,6 cm with 2,5 cm air introduced 
respectively. The width of the distal dose fall-off, the d80%-d20%, was unperturbed.  
 
 
 
 
 
 
 
Table 4-I: Variation in proton range (d90%) and distal dose falloff (d80%-d20%) in a water phantom following the 
introduction of volumes of bones and air of various thicknesses in the beam path. The depths where the beam reached 
the volumes are also listed.  
            Inserted material Bone (HU 1000) Air (HU -1000) 
Volume 
thickness 
(cm)  
Depth 
(cm) 
Range 
(cm) 
Distal dose 
fall-off 
(cm) 
Range 
(cm) 
Distal dose 
fall-off 
(cm) 
0,0 9,0 20,3 -0,5 20,3 -0,5 
0,5 8,5 20,0 -0,5 20,7 -0,5 
1,0 8,0 19,8 -0,5 21,3 -0,5 
1,5 7,5 19,5 -0,5 21,7 -0,5 
2,0 7,0 19,3 -0,5 22,2 -0,5 
2,5 6,5 19,1 -0,5 22,6 -0,5 
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Based on the data listed in Table 4-I, the change in range as a function of volume thickness 
is displayed in Figure 4-3. The trend lines, the polynomial equations obtained based on a fit 
to the data and the respective R2-values are also displayed. With respect to changes in the 
proton range, the results show that inserting a volume of air has a larger impact compared 
to inserting a bone volume. The slope of the range deviation as function of the inserted 
structure thickness was nearly twice as steep with the inserted air volumes compared to 
inserting bone volumes. For both scenarios the change of range as a function of thickness 
of the inserted volume was approximately linear. The air volume gave an increase of the 
range with a factor of !"!"  = 0,94, and the bone volume gave a reduction of range with a 
factor of !"!"  = -0,48.  
 
 
 
 
 
 
 
Figure 4-3: The change in range (d90%) as a function of volume thickness. The plot shows the result for volumes of air 
(blue squares) and bone (red circle). The fit-based polynomial trend line with and the associated R-squared value are 
displayed for both data sets. 
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The DVH for the target volume is showed in Figure 4-4. The DVH displays the results for 
the situations with the 2,5 cm thick volumes of bone and volume of air inserted in the 
beam path.  
 
Two main features are observable from the dose distribution for the target volume: Firstly, 
the target DVHs resulting from inserting bone compared to air followed (quite) different 
patterns. The main effect of the introduction of the bone structure was a lowering of the 
minimum dose delivered to the target, an effect that was of considerable smaller in 
magnitude in the DVHs after inserting air volumes. The reference Dmin = 96,5% was 
reduced to Dmin = 1,1% and Dmin = 85,3% due to inserted bone volumes and air volumes, 
respectively. The decrease in the 95% target dose coverage was larger from inserting air 
compared to bone. The V95% was reduced from the reference V95% = 100% to V95% = 89,2% 
for the situation with the bone volumes, and to V95% = 76,5% in the situation with air 
volumes. The results were similar for the bone and air volumes at both 2,5 cm and 6,5 cm 
depth. Secondly, the target volume DVHs for both inserted materials/density structures 
located at different depths coincided showing that the position in depth of the bone-
volume and air volume had no significant impact on the dose to the target volume. Similar, 
but less pronounced effects were seen after inserting volumes of smaller thickness.  
 
 
 
 
 
Figure 4-4: Dose Volume Histograms (DVH´s) for the target volume after the insertion of 2,5 cm volumes of air and 
bone at two different depths. DVH for the reference plan is also showed.  
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4.1.2 Effects of geometric errors 
Table 4-II lists the resulting Dmin, Dmax and V95% for the phantoms Awater, Bbone and Cair after 
5 mm isocenter shifts were introduced along the x-, z- and y-axis. The Dmin, Dmax and V95% 
for the reference plans with no isocenter shifts are also displayed. The shifts along the x- 
and z- axis were shifts orthogonal to the beam axis, while shifts along the y- axis were 
parallel to the central beam axis. Since all the water phantoms were symmetric, the shifts in 
the x-and z-direction were expected to have a similar effect on the dose distribution.  
 
Shifts along the y-axis had no noticeable impact on the minimum dose, maximum dose or 
the 95% target coverage in any of the phantoms, regardless of whether the shifts were 
towards the source (negative shifts) or away from the source (positive shifts). Shifts along 
the x-and z-axis caused a reduction in the Dmin relative to the calculated reference dose 
distribution in all the phantoms. Shifts along the x-axis caused the largest reduction in Dmin 
in phantom Awater. In phantom Bbone, the shift in the x-direction had a slightly larger impact 
on the Dmin compared to the shifts in the z-direction, while in phantom Cair the effect of 
shifts in the x- and z directions were comparable. Shifts in x- and z-direction caused an 
increase in Dmax in phantom Bbone and Cair, while Dmax was almost unaffected in phantom 
Awater. The 95% target coverage (V95%) was also degraded in all dose distributions with the 
largest reduction found in phantom Cair.  
 
 
Table 4-II: The effect of isocenter shifts on the Dmin, Dmax and V95% for the homogeneous phantom (Awater) and the 
heterogeneous phantoms (Bbone and Cair). Results are presented for the target volume with no shifts and after 5 mm shifts 
along the x-, z- and y-axis.  
                    
Parameter Dmin (%) Dmax (%) V95% (%) 
Plan/shifts Awater Bbone Cair Awater Bbone Cair Awater Bbone Cair 
Reference 95.0 95.0 95.0 103.5 104.4 108.6 100.0 100.0 100.0 
x+5 mm 72.3 65.6 70.4 103.5 111.5 112.9 97.6 96.6 96.0 
z+5 mm 79.4 70.9 69.6 103.5 108.1 114.4 97.8 97.0 96.4 
y+5 mm 95.0 94.9 95.1 104.0 104.9 109.9 100.0 100.0 100.0 
y-5 mm 95.1 95.0 95.1 103.1 104.0 108.1 100.0 100.0 100.0 
Abbreviations: Dmin: minimum dose delivered to target volume, Dmax: maximum dose delivered to target volume, V95%: 
Volume receiving at least 95% of prescribed dose. 
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The effects on the target dose homogeneity resulting from the geometric misalignments 
depended not only on the shift direction, but also differed between the various phantoms, 
as illustrated in Figure 4-5. The variation in the calculated HI is displayed for the reference 
plan with no shifts, and after the isocenter shifts for all the phantoms. The shifts of 
isocenter along the beam direction had hardly any impact on the HI as opposed to the 
shifts in x-and z- direction. In phantom Awater the HI was increased from 0,04 to 0,08 and 
0,09 for z and x shifts respectively. The similar result from phantom Bbone was an increase 
from 0,03 to 0,11 and 0,13. The largest effect of isocenter shifts was seen in phantom Cair 
with an increase in HI from 0,04 to 0,14 and 0,15 for isocenter shifts in z and x directions.  
 
  
 
 
 
Figure 4-5: Dose homogeneity in the target volume, expressed by the Homogeneity index (HI) for all three phantoms. 
The impact of isocenter shifts on the Homogeneity Index (HI) is displayed. The reference HI (no shifts) is also showed. 
A HI of 0 is ideal. The D98%, D2% and the D50% are used for the calculation of the HI. 
 
 
 
 
Figure 4-6 shows the total dose distribution (top panel) and the 95%-107% dose 
distribution (bottom panel) after lateral isocenter shifts of +5 mm. The dose distribution is 
displayed in colour wash for plans on water phantom Awater, Bbone and Cair. The isocenter 
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shift caused a loss in the 95% target coverage along the lateral border in all the phantoms. 
Two additional effects could also be seen distal to the target volume in the heterogeneous 
phantoms. In phantom Bbone, hotspots are apparent inside the target: Especially in line with 
the inner bony structure on the left hand side in the figure, as evident from the 95%-107% 
dose distribution. In the extension of this line indicating the bone, a small area of 50% 
dose level extended outside the target volume, as observed in the image with the total dose 
distribution in the upper middle panel. Moreover, an area of reduction in the 95% dose 
coverage was seen distally in the target volume on the contralateral side, this also in line 
with the lateral edge of the bone volume. A similar effect, now more pronounced, was seen 
for the phantom Cair, with the hotspot appearing on the distal left side of the air volume, 
and with decay in dose coverage at the distal right side.  
 
   
 
 
 
Figure 4-6: The effect on the dose distribution of a 5 mm lateral isocenter shift in homogeneous (A) and heterogeneous 
(B and C) water phantoms. The figure displays the total dose distribution in the top panels and the 95%-107% dose 
distribution in the panels below. The target volume is indicated by the red solid line.  
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Figures 4-7a-c) give a further illustration of the different effects presented in Figure 4-6, 
and show the lateral dose profiles in 20 cm depth, a depth that corresponds with the distal 
border of the target volume. Thus, the dose profiles coincide with the distal target 
boundary, as illustrated at the right top corner in the figures. The non-shifted dose profiles 
from the reference plans (solid lines) and the dose profiles after a 5 mm lateral shift are 
displayed for phantom Awater (Figure 4-7a)), phantom Bbone (Figure 4-7b)) and phantom Cair 
(Figure 4-7c)). The arrows in the figures indicate the direction of the isocenter shift. The 
dose profiles in phantom Bbone and Cair are distributed with a different pattern than the 
corresponding dose profile in phantom Awater. In all the phantoms all dose profiles were 
shifted in the same direction as the isocenter shift, with the magnitude of 5 mm at the 50% 
dose level. However, in addition to the spatial position shift of the dose profile for all 
phantoms, a substantial dose decrease and increase were observed along the dose profiles 
in both phantom Bbone and Cair. The alteration in dose appeared in line with the lateral edges 
of the inner structure in both phantoms. In phantom Bbone the dose reduction occurred at 
the left edge of the inner structure, with the dose dropping to 65,6% of prescribed dose, 
corresponding to the Dmin in the dose plan. The increase in dose appeared at the 
contralateral side, at the right edge. A similar pattern was seen in phantom Cair, but in this 
case, the situation was the inverse compared to the situation in phantom Bbone, with a dose 
increase and a dose decrease at the opposite sides of the inner structure.   
 
 
 
 66 
 
Figure 4-7: The lateral dose profiles at 20 cm depth, which corresponds to the distal border of the target as showed in 
figure on left top in the figures, are displayed in a) for phantom Awater, in b) for phantom Bbone and in c) for phantom Cair. 
The dose profiles from the reference plan (solid lines) and the +5 mm lateral shifted plan (dashed lines) are presented. 
The direction of the shift is indicated with the arrows. Distance = 0 equals the centre of the phantom. 
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4.2 The craniospinal treatment plans  
In this section the results for the robustness analysis of the craniospinal treatment plans are 
presented. An evaluation of the reference treatment plans, which were used as basis for the 
simulations of the various errors, are given in 4.2.1, the results from the simulations of the 
calibration curve errors (CCE) are presented in 4.2.2 and the results from the simulation of 
the setup errors are presented in 4.2.3.  
 
4.2.1 Evaluation of the dose distribution in the reference treatment plans 
4.2.1.1  Dosimetr i c  data for  the target  vo lumes  
In Table 4-III the dose statistics for the PTV, the CTV, the brain and the spinal canal are 
summarized for the 6 study patients. The mean values with standard deviations are 
presented for 5 different parameters: the Dmin, Dmax, D98%, D2% and V95%. The V95% equals 
V34,2Gy (RBE) and corresponds to the target volume dose coverage. Generally the plans had 
satisfactory target volume dose coverage. For the CTV, the brain and the spinal canal, the 
V95% was a 100%, and for the PTV it was 99,9%. For all the target volumes the near 
minimum dose, D98%,, was better than 95% of the prescribed dose, ranging from 97.8 % of 
the prescribed dose for the PTV (lowest) to 98% of the prescribed dose for the CTV 
(highest). The near-maximum dose, D2%, was less than 103% in all target volumes. The 
results were consistent across the patient group, as also demonstrated by the low standard 
deviations.  
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Table 4-III: The table lists the descriptive statistics for 5 different parameters for the PTV, the CTV, the brain and the 
spinal canal volume. Mean values and standard deviations are presented for D98%, D2%, V95%, Dmin and Dmax. 
                  
 PTV CTV Brain Spinal canal 
Parameter Mean (%) SD Mean (%) SD Mean (%) SD Mean (%) SD 
D98% 97,8 0,3 98,0 0,2 97,9 0,3 98,0 0,2 
D2% 102,8 0,6 102,3 0,7 102,4 0,7 101,8 0,2 
V95% 99,9 0,1 100,0 0,0 100,0 0,0 100,0 0,0 
Dmin 84,4 4,7 93,4 1,1 94,7 0,7 96,3 0,5 
Dmax 111,9 2,0 111,1 2,5 111,1 2,5 105,6 1,5 
Abbreviations: Dmin = minimum dose delivered to target, Dmax= maximum dose delivered to target, V95%: Volume 
receiving at least 95% of prescribed dose, D98% = least dose received by 98% of target volume, D2%= least dose received 
by 2% of target volume. 
 
 
Figure 4-8a-d) shows the dose distribution for patient II. The total dose distribution is 
displayed in sagittal plane in a) and in transversal plane in c), while the 95% -107 % dose 
distribution is displayed in the sagittal plane in b) and the transversal plane in d). The 95% 
isodose covers the brain, the spinalcanal and the entire corpus vertebra with a homogenous 
dose as displayed in Figure 4-8b). A few hotspots can be observed towards the surface of 
the cranium (Fig. 4-8d)). There is a rapid dose falloff providing sparing of the tissue ventral 
to the vertebrae (Fig 4-8a) and c)).  
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Figure 4-8: The dose distribution for patient II: The total dose distribution is displayed in the sagittal plane in a) and the 
transversal plane in c). The 95%-107% dose distribution is displayed in the sagittal plane in b) and the transversal plane in 
d). The dose levels are scaled as displayed by the colour bar in a) and b). 
 
 
 
The dose conformity and homogeneity for the PTV was evaluated by means of the CI, the 
CN and the HI. The result is presented in Table IV, which lists the mean values and the 
standard deviation for the CI, CN and HI. For the calculation of the indices the D2%, D98% 
and D50% were used for the computation of the HI, and the V95% was used for the 
calculation of the CI and CN. The CI for the PTV was 1,0 for all the patients (SD =0). 
Similarly, the CN was 0,87 with a standard deviation of 0,02. The HI was 0,05 for the PTV 
with a standard deviation of 0,01.  
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Table 4-IV: The table presents the group averaged CI and CN and HI for PTV. The standard deviation is also displayed.    
        
PTV 
Index HI CI CN 
Mean 0,05 1,00 0,87 
SD 0,01 0,00 0,02 
 
 
 
 
4.2.1.2  Dosimetr i c  data for  the OAR 
Descriptive statistics for the doses to the OAR are summarized in Table 4-V.  
 
The Dmean to the heart was 0,6 Gy (RBE) with a SD of 0,3. The Dmean for the left kidney 
was 1,8 Gy (RBE) with a SD of 0,4.  For the right kidney, the Dmean was 2,0 Gy (RBE) with 
a SD of 0,4.  
 
The highest doses could be seen in the eyes with e.g. a Dmean of 11,7 Gy (RBE) with a SD 
of 2,1, and a Dmean of 12,4 Gy (RBE) with a SD of 1,8 for the left and right eye, 
respectively. This corresponds to 32,5% and 34,4% of the prescribed dose. 
 
The mean doses to the thyroid ranged between 2,9 Gy (RBE), corresponding to 8% of 
prescribed dose, and 11,5 Gy (RBE), corresponding to 31,9% of prescribed dose, with an 
average of 7,2 Gy (RBE), corresponding to 20% of prescribed dose. The large spread in 
the data for the thyroid could also be seen in the V5Gy (RBE) and V10Gy (RBE).  
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Table 4-V: Descriptive dose statistics for the lenses, lungs, heart, kidneys, thyroid and eyes. The results for V5Gy (RBE), 
V10Gy (RBE) and V20Gy (RBE) are displayed in relative values (%). Results for Dmean and Dmax are displayed in absolute values 
[Gy (RBE)].  
	   	   	   	   	   	   	   	   	   	   	  
Structure,	  
dose	  
statistics	  
Mean	   SD	   Min	   Max	   	  
Structure,	  
dose	  
statistics	  
Mean	   SD	   Min	   Max	  
Left	  lens	   	   	   	   	   	   Right	  lens	   	   	   	   	  
Dmean	  	   3,7	   0,9	   2,5	   4,7	   	   Dmean	  	   3,8	   0,9	   2,7	   4,9	  
Dmax	  	   7,0	   1,5	   4,8	   9,1	   	   Dmax	  	   7,0	   1,5	   5,2	   9,0	  
Heart	   	   	   	   	   	   Thyroid	   	   	   	   	  
Dmean	  	   0,6	   0,3	   0,3	   1,2	   	   Dmean	  	   7,2	   3,3	   2,9	   11,5	  
Dmax	  	   25,4	   6,1	   19,5	   37,0	   	   Dmax	  	   29,9	   1,8	   27,0	   31,9	  
V5Gy	  (RBE)	   4,2	   2,1	   1,9	   7,7	   	   V5Gy	  (RBE)	   51,0	   27,3	   16,4	   82,4	  
V10Gy	  (RBE)	   1,7	   1,3	   0,6	   4,2	   	   V10Gy	  (RBE)	   28,7	   15,1	   10,2	   51,1	  
V20Gy	  (RBE)	   0,2	   0,4	   0,0	   1,1	   	   V20Gy	  (RBE)	   7,4	   4,8	   3,6	   16,6	  
Left	  lung	   	   	   	   	   	   Right	  lung	   	   	   	   	  
Dmean	  	   2,3	   0,5	   1,5	   3,2	   	   Dmean	  	   3,2	   0,6	   2,0	   3,6	  
Dmax	  	   35,5	   0,6	   34,5	   36,2	   	   Dmax	  	   35,9	   0,4	   35,4	   36,4	  
V5Gy	  (RBE)	   13,4	   2,8	   8,9	   17,6	   	   V5Gy	  (RBE)	   16,9	   3,3	   10,4	   19,2	  
V10Gy	  (RBE)	   8,8	   2,1	   5,9	   12,3	   	   V10Gy	  (RBE)	   12,1	   2,3	   7,6	   13,7	  
V20Gy	  (RBE)	   3,6	   1,2	   2,3	   5,9	   	   V20Gy	  (RBE)	   6,5	   1,3	   4,1	   7,8	  
Left	  kidney	   	   	   	   	   	   Right	  kidney	   	   	   	   	  
Dmean	   1,8	   0,4	   1,4	   2,5	   	   Dmean	   2,0	   0,4	   1,4	   2,6	  
Dmax	   31,0	   3,4	   24,7	   34,1	   	   Dmax	   30,2	   1,9	   27,7	   33,2	  
V5Gy	  (RBE)	   11,9	   2,4	   8,8	   16,2	   	   V5Gy	  (RBE)	   13,0	   2,7	   9,1	   16,7	  
V10Gy	  (RBE)	   5,7	   1,3	   4,9	   8,1	   	   V10Gy	  (RBE)	   6,2	   1,4	   4,5	   8,2	  
V20Gy	  (RBE)	   1,3	   0,6	   0,5	   2,3	   	   V20Gy	  (RBE)	   1,4	   0,5	   0,9	   2,0	  
Left	  eye	   	   	   	   	   	   Right	  eye	   	   	   	   	  
Dmean	   11,7	   2,1	   9,8	   15,5	   	   Dmean	  	   12,4	   1,8	   10,1	   14,3	  
Dmax	   34,3	   1,1	   32,9	   36,0	   	   Dmax	  	   34,5	   1,0	   32,7	   35,6	  
V5Gy	  (RBE)	   67,7	   8,5	   58,4	   79,9	   	   V5Gy	  (RBE)	   70,0	   6,9	   62,8	   77,7	  
V10Gy	  (RBE)	   48,6	   8,5	   40,3	   62,1	   	   V10Gy	  (RBE)	   51,7	   7,5	   42,4	   60,0	  
V20Gy	  (RBE)	   21,7	   7,1	   16,1	   35,3	   	   V20Gy	  (RBE)	   24,8	   6,5	   15,8	   31,3	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4.2.2 Effects of calibration curve errors 
4.2.2.1  The Max-Min dose dis tr ibut ion 
Figure 4-9 shows the calculated Max-Min dose distribution for patient IV resulting from 
imposed calibration curve errors (CCE) from +1% to 5% (representing undershoot) and 
from -1% to 5% (representing undershoot). Hence, 10 different error distributions, as well 
as the reference dose distribution, are included in the calculation of the Max-Min dose 
distribution. Note that the images do not show the change in the dose relative to the 
reference plan, but the calculated differences between the maximum and minimum dose at 
each point. The dose differences are scaled as displayed by the colour bar to the right in 
Figure 4-9. Clearly the dose differences were small within the target volumes. Distal to the 
PTV the differences were more apparent, exposing a band along the spine of which the 
dose differences were of more than 40%.  
 
 
  
 
 
 
Figure 4-9: The Max- Min dose distribution after CCEs of ±1% to ±5%. The dose difference is displayed by the colour 
bar to the right in the image. 
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4.2.2.2  Dose coverage for  the target  vo lumes 
The overall dosimetric effect of the 1% to 5% overshoot and the 1% to 5% undershoot is 
presented for one representative patient in Figure 4-10a-d). The figure displays both the 
DVH for reference plan (the solid lines) and the recalculated error DVHs (the dotted lines) 
for the spinal canal and the brain.  The resulting DVHs following a 1% to 5 % overshoot is 
showed in Figure 4-10a) for the spinal canal and in Figure 4-10c) for the brain. The 
resulting DVHs following 1% to 5 % undershoot is presented in Figure 4-10b) for the 
spinal canal and in Figure 4-10d) for the brain.  
 
 
The  ±1% to ±5% CCEs had no large impact on the overall doses to the spinal canal or the 
brain. The analysis of the DVHs for the brain, and to some extent for the spinal canal, 
revealed a very small, but systematic reduction in the doses following the 1% to 5% 
overshoot, this demonstrated by the systematically shifted error curves toward the lower 
dose levels.   
 
A comparable, but opposite effect could be observed for the spinal canal after the 1% to 
5% undershoot; the error DVHs were systematically shifted in very small steps towards the 
higher doses. The error DVHs for the brain showed a slightly different pattern. 
Undershoot reduced the steepness of the DVH curve and resulted in an increased Dmax, a 
reduced Dmin and consequently a less homogenous dose distribution.   
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Figure 4-10: DVH from patient III showing the effect on the CTV after introducing a CCE of -1% to -5% on the top 
panel (the overshoot situation), and +1% to +5% on the bottom panel (the undershoot situation). The solid lines 
represent the reference plan, and the dotted lines the error curves. The dose is displayed on the x-axis from the 90% level. 
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The plot in Figure 4-11 shows the V34,2 Gy (RBE) (V95% )  as a function of the CCE magnitude. 
Group-averaged results are presented for the brain, the spinalcanal and the CTV. The V34,2 
Gy (RBE)  for the reference plan, which had 0% CCE, is also displayed. The scale on the y-axis 
starts at 96%.  
 
Figure 4-11 shows that the spinalcanal sustained the 95% dose coverage regardless of any 
CCE. The overshoot of 1-5% did not affect the V34,2 Gy (RBE) for the brain and the CTV, nor 
did a 1% undershoot. With a further undershot of 2-5 % an increasingly reduction in the 
V34,2 Gy (RBE) for the brain and CTV was seen. The situation with a 4% and 5 % undershoot 
resulted in a reduction of the V34,2 Gy (RBE) for the brain from 100% to 98,4 % and 97,1% 
respectively. Similarly, with a 4% and 5 % undershoot the V34,2 Gy (RBE)  for the CTV was 
reduced to 98,5 % and 97,4%, respectively. For the 2% and 3% undershoot the 95% dose 
coverage was slightly reduced, but still > 99% for both the brain and the CTV. 
 
 
 
 
 
Figure 4-11: The plot presents the mean result for V34,2 (Gy (RBE)) across the patients as a result of 1% to 5% overshoot and 
1% to 5% undershoot. The effects on the CTV, the brain and the spinal canal are presented. The magnitude of the CCEs 
is displayed on the x-axis and the V34,2 Gy (RBE) is displayed on the y-axis. 
 
 
 
Figure 4-12a-c) shows the 95%-107% dose distribution for the brain for patient VI in the 
transversal view. The dose distribution is displayed for the plan with no CCE in image a), 
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the dose distribution after a 5% overshoot is presented in image b) and after a 5% 
undershoot in image c). The yellow arrows indicate the beam direction of the cranial 
treatment fields.  
 
Compared to the reference plan displayed in Figure 4-12a), both overshoot and undershoot 
resulted in increased dose inhomogeneity throughout the brain, this displayed by the 
increased amount of hot spots (indicated by the red arrows in image b) and c)) and cold 
spots (indicated by the blue arrows in the images). A loss in the 95% dose coverage, caused 
by the 5% undershoot is clearly visible in Figure 4-12c). The cold spots appeared for the 
large part laterally in the brain, towards the cranium, but could also be observed well inside 
the brain. A band of hot spots could also be seen at the right side of the brain. In Figure 4-
12b), which displays the consequence of the overshoot, increased amount of hotspots 
could be observed. These hotspots appeared for a large part in, or in relation with, the 
bony structures of the skull.   
  
 
 
 
 
Figure 4-12: The 95% -107% dose distribution displayed for the reference treatment plan for patient VI in a). The 
corresponding dose distribution after a 5% overshoot displayed in b) and after a 5% undershoot in c). The yellow arrow 
indicates the beam direction of the cranial treatment fields, the red and blue arrows indicates the hot spots and cold spots, 
respectively.  
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4.2.2.3  Doses to the organs r i sk 
In Figure 4-13a-b) the DVHs from one representative patient are presented, demonstrating 
how the ± 1 to ±5% CCEs influenced the overall doses to the OAR. The figure displays 
the DVH from the reference plan (the solid lines), and the recalculated error-DVHs, each 
of which contains a single value of the CCE (dotted lines). DVHs for the right eye, the 
thyroid, the heart and the right kidney are displayed. The resulting DVHs following a 1% 
to 5 % overshoot is showed on the top panel, while the resulting DVHs following 1% to 
5% undershoot is presented on the bottom panel.  
 
Generally, an increasing overshoot caused a continuous increase in doses to the OARs, this 
demonstrated by the systematically shifted DVHs. A similar, but opposite effect were seen 
following an increasing undershoot, which resulted in a continual dose-reduction. The 
dose-increase induced by the overshoot appeared to be more pronounced than the dose-
decrease induced by undershoot. This is demonstrated by the greater dispersion between 
the reference DVHs and the error DVHs in the figure on top panel of the figure. Further, 
the thyroid suffered the largest changes in dose. The eyes and the heart were only slightly 
affected, while the impact on the dose to the kidneys and lungs were insignificant.  
 
 
 78 
 
Figure 4-13: DVHs with error curves from patient IV after overshoot and undershoot of 1% to 5%. The result for heart, 
right kidney, right eye and thyroid is presented in a) after overshoot and in b) after undershoot. The solid lines represent 
the reference curves from the plan with no errors, and the dashed lines represent the error curves.  
 
 
 
Figure 4-14 presents the resulting Dmean, including the group-averaged value, for the heart 
for patient I-VI after CCEs from ±1% to ±5%. The 0% represents the Dmean from the 
reference plan. Compared to the reference plans, the overshoot caused a gradually increase 
of the Dmean, while the opposite effect could be observed for the undershoot. Although the 
individual Dmean differed between the patients, the changes revealed for the most part a 
similar tendency, with an approximately equal increase or decrease in dose, except for 
patient V, which seemed to be affected, especially by the overshoot, to a greater extent 
than the other patients. However, for all patients, the changes in Dmean were in general small 
and the results displayed moderate changes.  
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Figure 4-14: The individual results for the Dmean following CCEs of ±1% to ±5%. The results for patient I-VI, including 
the mean values across the patient group, are displayed. Zero % CCE corresponds to the reference plans.  
 
 
 
In Figure 4-15 the resulting Dmean for the thyroid stemming from the over-and undershoot 
from 1% to 5% is displayed for patient I-VI. The 0% represents the Dmean from the 
reference plan and the group-averaged Dmean is also displayed.  
 
Approximately equal trends could be observed for all the patients. The Dmean experienced a 
systematic and gradually increases as a result of the imposed overshoot of 1% to 5%, while 
a continuous decrease in Dmean followed the increasing undershoot.  
 
A 3% overshoot resulted in an increase of the group-averaged Dmean in the order of almost 
3 Gy (RBE), from 7,2 Gy (RBE) in the reference plan, to 10,1 Gy (RBR), which 
corresponds to a dose difference of 47%. The Dmean after the 4% and 5% overshoot were 
11,3Gy (RBE) and 12,5Gy (RBE), corresponding to a dose change of the order of 66% 
and 87%, respectively. 
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 Figure 4-15: The individual results for the Dmean following CCEs of ±1% to ±5%. The results for patient I-VI, including 
the mean values across the patient group are displayed. Zero % CCE corresponds to the reference plans.  
 
 
4.2.3 Effects of setup errors 
In Figure 4-16a-c) the Max-Min dose distribution after the simulation of the setup errors is 
displayed for patient II. The result from the present calculation is representative for the 
rest of the patient group. Following setup errors of ±1 to ±5 mm in 1 mm steps in the left 
and right direction the Max-Min dose differences were calculated, the result of this 
calculation is displayed in Figure 4-16a) in coronal view. Corresponding calculations were 
also performed for the setup errors in the ventral and dorsal directions, and for the setup 
errors in caudal and cranial the directions. The results from these calculations are shown in 
Figure 4-16b) and Figure 4-16c), both in sagittal view. The dose differences are displayed 
by the colour bar scale to the right in each image.  
 
The largest Max-Min dose differences following the left and right setup errors, emerged 
bilaterally along the spine, with dose differences well above the 60% level. Following 
vertical setup errors, the Max-Min dose differences of more than 40% were mainly seen in 
the cranium and in the cranial part of the cervical spine. Following cranial and caudal setup 
errors Max-Min dose differences of more than 40% appeared in the cranial and the caudal 
part of the patient. The Max-Min dose differences were largest outside the PTV for all 
setup errors in any directions. 
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Figure 4-16: The calculated Max-Min dose distribution after setup errors of ±1to ±5 mm in the longitudinal, lateral and 
vertical direction is presented. Image a) displays the result in the coronal plane after lateral setup errors, image b) and c) 
displays the result in the sagittal plane after vertical and longitudinal setup errors, respectively.   
 
 
 
4.2.3.1  Target  vo lume dose coverage  
Figure 4-17a-c) shows the impact of setup errors of 1-5 mm on the 95% dose coverage 
(V34,2 Gy (RBE) ) for the CTV, the brain volume and the spinal canal. The figure displays the 
group-averaged results for the V34,2 Gy (RBE) (%) after the introduction of  setup errors in the 
caudal and cranial directions (Figure 4-17a)), in the dorsal and ventral directions (Figure 4-
17b)) and in the left and right directions (Figure 4-17c)). The magnitude of the shifts are 
displayed on the x-axis, and the V34,2 Gy (RBE) on the y-axis, in relative units. Note that the 
scale on the y-axis starts at 96%.  
 
In general, setup errors had only minor influence on the V34,2 Gy (RBE).  Regardless of the 
magnitude of the errors, the resulting V34,2 Gy (RBE) remained > 97% for all the volumes. 
Some differences between the target volumes could be observed, though. The spinal canal 
sustained the 95% dose coverage irrespective of any setup error, with the exception of the 
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5 mm setup error in the cranial and ventral direction. The resulting loss in the 95% dose 
coverage was nonetheless diminutive with V34,2 Gy (RBE)= 99,7% and V34,2 Gy (RBE)= 99,9%  due 
to the cranial and ventral setup errors, respectively.  
 
The V34,2 Gy (RBE) for the brain volume and the CTV exhibited similar tendencies following 
the caudal and cranial setup errors, and the dorsal and ventral set up errors , while some 
differences between the two volumes could be observed after the setup errors in the left 
and right directions. For both volumes the caudal setup errors were of most importance, 
however with minor reductions in the resulting V34,2 Gy (RBE). The largest consequence was 
seen in the brain volume, with the 2 mm and 5 mm error reducing the V34,2 Gy (RBE) to 99,6% 
and 97,2%, respectively.  
 
The setup errors in the left and right directions had an insignificant effect on the V34,2 Gy 
(RBE) for the brain volume and only a small effect for the CTV. All reductions in V34,2Gy (RBE) 
for the CTV were less than 2 %.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 83 
 
 
 
Figure 4-17: The impact of setup errors on the V34,2Gy (RBE) for the CTV, the brain and the spinal canal. The group-
averaged results are displayed for caudal and cranial setup errors in a), for dorsal and ventral setup errors in b) and for left 
and right setup errors in c). The magnitude of shifts are displayed on the x-axis and the V34,2Gy (RBE) on the y-axis in 
relative units. The zero shifts represent the values from the reference plans. Note that the scale on the y-axis starts at 
96%. 
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In Figure 4-18a) the dose distribution is displayed for the reference plan. Figure 4-18b) 
displays the dose distribution after a 5 mm lateral setup error is introduced. The images 
show the CTV (marked with the red line) and the spinal canal (marked with the cyan line) 
in the mediastinum level in the transversal view. The yellow arrows in the figures indicate 
the beam direction.  
 
Two main effects could be observed as a result of the setup error. Firstly, the 5 mm lateral 
setup error resulted in a shift of the dose distribution in the same direction as the setup 
error was applied.  The consequence was a loss in the CTV dose coverage as indicated by 
the red arrow in imaged 4-18b). The 95% dose coverage to the spinal canal was however 
sustained. Secondly, a significant disturbance of the dose distribution could be observed. 
The setup error clearly caused an overall increase of the lung doses, as displayed by the 
80%-105% isodose lines. The 80%-105% isodose became significantly extended distally, as 
indicated by the pink arrow in the figure.  
 
 
 
 
 
Figure 4-18: The dose distribution is displayed by isodose lines for the plan without an applied setup error in image a). 
The dose distribution after a 5 mm lateral setup error (indicated by the white arrow) is displayed in image b). The beam 
direction is indicated by the yellow arrow. The red arrow indicates the loss in the target volume dose coverage. The pink 
arrow indicates the error influenced high dose area. 
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The Figure 4-19 shows the 95% -107% dose distribution in transversal view for the 
reference plan in image 4-19a), the 95%-107% dose distribution after a setup error of 5 
mm in the dorsal direction in image 4-19b), and after a setup error of 5 mm in the ventral 
direction in image 4-19c).  
 
An almost contradictory effect could be observed when comparing the resulting dose 
distribution of the ventral and the dorsal setup errors. Following the dorsal setup error, hot 
spots emerged in the cranium at the dorsal part of the skull, as indicated by the red arrow. 
In the same area the setup error in the ventral direction resulted a loss in the 95% dose 
coverage, this indicated by the blue arrow. In the ventral part of the brain, between the 
eyes, the similar tendency could be seen, but now instead with the hot spots and the cold 
spots stemming from the ventral and dorsal setup errors, respectively. In the image with 
the applied ventral shift, a band of hot spots is visible at the left side of the brain. The same 
can also be observed at the right side of the brain, here to a lesser extent. The dose 
perturbations triggered by the setup errors appeared for the most part in the areas where 
the dose distribution in the reference plan was most inhomogeneous.  
 
 
 
 
 
 
 
Figure 4-19: The 95%-107% dose distribution displayed in transversal view. The dose distribution from the reference 
treatment plan is displayed in image a). The dose distribution from the plan with the imposed setup error of 5 mm in the 
dorsal and the ventral directions are displayed in image b) and in image c) respectively. The blue and red arrows indicate 
areas with cold spots and hot spots, respectively. 
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The 95% -107% dose distribution following the introduction of a 5 mm setup error in the 
caudal and cranial directions is displayed in sagittal view in Figure 4-20b) and 4-20c), 
respectively. The corresponding dose distribution for the reference plan is displayed in 
Figure 4-20a). The perturbations of the dose distribution stemming from the setup errors 
in the caudal and cranial directions emerged for the most part in the cranial portion of the 
brain, and in the area related to the skull base. As also demonstrated for the dorsal and the 
ventral setup error, virtually opposite trends could be observed. The cranial setup error 
induced a formation of hot spots in the cranium, indicated by the red arrow in image 4-
20c). The cranial setup error also reduced the 95% dose coverage in the skull base area. 
The resulting cold spot is indicated by the blue arrow in the image. The caudal setup error, 
however, resulted in the appearance of cold spots in the cranial part of the brain, this 
indicated by the blue arrow in image 4-20b), and of hot spots in the skull base area, this 
indicated by the blue arrow in the image.    
 
 
 
 
 
Figure 4-20: The 95%-107% dose distribution is displayed in sagittal view. The dose distribution from the reference 
treatment plan is displayed in image a). The dose distribution from the plan with the imposed setup error of 5 mm in the 
caudal and the cranial directions are displayed in image b) and in image c), respectively. The blue and red arrows indicate 
areas with cold spots and hot spots, respectively. 
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4.2.3.2  Doses to organs at  r i sk 
In the following, the resulting Dmean and V5Gy (RBE) from the simulations of the 1 mm to 5 
mm setup errors are presented. Individual results and mean results across the patient group 
(so-called group-averaged results) are presented for the heart, the thyroid, the kidneys and 
the eyes in Figures 4-21 to 4-29.  
 
 
The doses to the heart 
The Figure 4-21 displays the group-averaged results for the V5Gy (RBE) for the heart following 
setup errors of 1-5 mm. The heart doses were mainly affected by the setup errors in the 
lateral directions, with a continuous increase or decrease in V5Gy (RBE). The V5Gy (RBE) 
increased from 4,2% in the reference plan to 5,0% and 6,8% after 2 mm and 5 mm setup 
errors in the left direction, respectively. In contrast, the corresponding setup errors in the 
right direction caused a slight reduction of the V5Gy (RBE) to 3,5% and 3%, respectively. 
Furthermore, the effects of the setup errors in the other directions were insignificant, no 
noticeable increase or decrease in V5Gy (RBE) could be observed.  
 
 
 
 
 
Figure 4-21: The resulting group-averaged V5Gy (RBE) for the heart following setup errors of 1 mm to 5 mm are displayed. 
The setup errors are displayed on the x-axis. The Dmean is displayed on the y-axis. The zero setup error represents the 
value from the reference plan.   
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Figure 4-22 displays the individual results for the Dmean for the heart following setup errors 
of 1-5 mm. The figure displays the result for patients I-VI, including the mean values for 
the patient group. Considerable variations in the Dmean could be observed between the 
individual patients, however, the effect of the setup errors where consistent with a small 
increase in Dmean stemming from the setup errors in the left direction. For the patient with 
the overall highest doses, patient V, the Dmean increased from 1,2 Gy (RBE) in the reference 
plant to 1,3 Gy (RBE) and 1,9 Gy (RBE) after the introduction of 2 mm and 5 mm setup 
errors in the left direction, respectively. Similar, for the patient with the lowest doses, 
patient VI, the Dmean increased from 0,3 Gy (RBE) in the reference plan to 0,4 Gy (RBE) 
and 0,6 Gy (RBE), respectively.  
 
 
 
 
 
Figure 4-22: The individual results for the Dmean for the heart following setup errors of 1-5 mm are displayed. The figure 
displays the result for patient I-VI including the mean values across the patient group. The setup errors are displayed on 
the x-axis and the Dmean on the y-axis. The zero shifts correspond to the reference plan. 
 
 
The doses to the kidneys 
The Figure 4-23 displays the group-averaged results for the V5Gy (RBE) for the right kidney 
following introduction of setup errors of 1-5 mm. As can be seen from this figure, only 
lateral setup errors influenced the doses to the kidneys. A rapid expansion in V5Gy (RBE) could 
be observed as a consequence of increasing setup errors in the right direction, from 13% in 
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the reference plan to 19% and 29% after the introduction of 2 mm and 5 mm setup errors, 
respectively. The opposite could be observed following the setup errors in the left 
direction. Here the corresponding results were 8% and 3%. The plot also illustrates that the 
doses to the kidneys are virtually unaffected by shifts in the longitudinal and vertical 
directions.  
 
 
 
 
 
Figure 4-23: The resulting group-averaged V5Gy (RBE) for the right kidney following setup errors of 1 mm to 5 mm are 
displayed. The setup errors are displayed on the x-axis. The V5Gy (RBE) is displayed on the y-axis. The zero setup error 
represents the value from the reference plan.   
 
 
 
 
The Figure 4-24 displays the individual results for the Dmean for the left kidney following 
the introduction of setup errors of 1-5 mm. The figure displays the result for patient I-VI, 
including the mean values across the patient group. Setup errors in the direction towards 
the left kidney had a dose-increasing effect. The opposite effect was seen when applying 
setup errors directed away from the left kidney, to a lesser extent though. The results for 4 
of the 6 patients showed similar behaviour with an approximately equal increase or 
reduction in the Dmean. As for the heart, the result for patient V displayed a more rapid 
increase in Dmean than the rest. The Dmean changed from 2,5 Gy (RBE) in the reference plant 
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to 3,9 Gy (RBE) and 6,5 Gy (RBE) after 2 mm and 5 mm setup errors toward the left, 
respectively. For the patient displaying the overall lowest doses, patient II, the Dmean 
changed from 1,4 Gy (RBE) to 2,0 Gy (RBE) and 3,3 Gy (RBE), respectively.     
 
 
 
 
 
Figure 4-24: The individual results for the Dmean for the left kidney following the introduction of setup errors of 1-5 mm 
are displayed. The figure displays the result for patient I-VI including the mean values across the patient group. The setup 
errors are displayed on the x-axis and the Dmean on the y-axis. The zero shifts correspond to the reference plan. 
 
 
 
The doses to the thyroid 
The Figure 4-25 displays the group-averaged results for the Dmean for the thyroid following 
the introduction of setup errors of 1-5 mm. The thyroid doses were mainly affected by the 
setup errors in the ventral and dorsal direction. Compared to the reference plan the ventral 
setup errors appeared as the most important dose-increasing parameter, with e.g. the Dmean 
changing from 7,2 Gy (RBE) in the reference plan to 8,2 Gy (RBE) and 9,7 Gy (RBE) in 
the plans recalculated with the 2 mm and 5 mm ventral setup errors, respectively. A 
somewhat more moderate increase in dose was seen as a consequence of the cranial setup 
errors. The opposite tendency was found following the dorsal and caudal setup errors, with 
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a steady diminishing Dmean. Furthermore, the right and the left shifts did not alter the Dmean 
significantly. 
 
 
 
 
 
Figure 4-25: The resulting group-averaged Dmean for the thyroid following setup errors of 1 mm to 5 mm. The setup 
errors are displayed on the x-axis. The Dmean is displayed on the y-axis. The 0 setup error represents the value from the 
reference plan.   
 
 
 
The Figure 4-26 displays the individual results for the V5Gy (RBE) for the thyroid following 
the introduction of setup errors of 1-5 mm. The figure displays the result for patient I-VI, 
including the mean values for the patient group.  Large variation could be observed from 
patient to patients, both regarding the doses in the reference plans, which range from 16% 
for patient II to 82% for patient VI, but also to which extent the setup errors affected the 
doses.  
 
Most consistent was the results for patient II with the V5Gy (RBE) changing from 16% in the 
reference plan to 17,2% and 20,4% following the setup errors of 2 mm and 5 mm in the 
ventral direction, respectively. The results for patient V and patient VI exhibited a different 
pattern than the results for the other patients with a more rapid dose-increase seen for 
these two. For patient V, the V5Gy (RBE) increased from 70,9% in the reference plan to 80,5% 
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and 89,8% in the plans with the 2 mm and 5 mm setup errors, respectively. The 
corresponding results for patient VI yielded a fluctuation in V5Gy (RBE) from 82,4% to 95,3% 
and 99,7%, respectively. 
 
 
 
 
 
 
Figure 4-26: The individual results for the V5 Gy (RBE) for the thyroid following setup errors of 1-5 mm are displayed. The 
figure displays the result for patient I-VI including the mean values across the patient group. The setup errors are 
displayed on the x-axis and the Dmean  is displayed on the y-axis. The zero shifts correspond to the reference plan. 
 
 
 
The doses to the eyes 
The Figure 4-27 displays the group-averaged results for the Dmean for the right eye 
following the introduction of setup errors from 1 mm to 5 mm. The setup errors in the 
caudal, cranial, dorsal and ventral directions were most important when it came to the 
consequences for the eye doses. Following increasingly larger shifts in both the caudal and 
ventral directions, a continuous increase in the Dmean was found. The dose increase was 
slightly larger as a consequence of caudal shifts. The dorsal and cranial shifts caused an 
almost equal reduction in the Dmean. Furthermore, the lateral shifts only had a negligible 
impact on eye doses.  
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Figure 4-27: The resulting group-averaged Dmean for the right eye following the introduction of setup errors from1 mm to 
5 mm. The setup errors are displayed on the x-axis. The Dmean is displayed on the y-axis. The 0 setup error represents the 
value from the reference plan.   
 
 
Figure 4-28 displays the individual results for the V5Gy(RBE for the left kidney following the 
introduction of setup errors from 1mm to5 mm. The figure displays the result for patient I-
VI including the mean values across the patient group.  
 
It was found that almost identical patterns could be seen for all the patients. The group-
averaged V5Gy(RBE, represented by the black triangles, changed from 67,9% in the reference 
plan to 74,9% and 84% in the plans with the 2 mm and 5 mm setup errors, respectively. 
Following the cranial setup errors of the same magnitude the V5Gy(RBE changed to 60,2% 
and 48,2%, respectively. For the results for patient VI, a small deviation in from the rest of 
the patients could be observed in the situation with the cranial shifts, with a slightly 
dampened reduction in V5Gy (RBE). 
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Figure 4-28: The individual results for the V5 Gy (RBE) for the left eye following the introduction of setup errors from 1-5 
mm are displayed. The figure displays the result for patient I-VI including the mean values across the patient group. The 
setup errors are displayed on the x-axis and the Dmean on the y-axis. The zero shifts correspond to the reference plan. 
 
 
 
Figure 4-29 displays the individual results for the Dmean for the right eye following the 
introduction of setup errors from 1-5 mm. The figure displays the result for patient I-VI 
including the mean values for the patient group. The results reveal that the dosimetric 
effects of the dorsal and ventral setup errors were consistent across the patient group. The 
group-averaged Dmean, represented by the black triangles, changed from 12,4 Gy (RBE) in 
the reference plan to 14,8 Gy (RBE) and 18,7 Gy (RBE) after the introduction of 2 mm 
and 5 mm shifts, respectively. Following the dorsal setup errors of the similar magnitude 
the Dmean changed to 10,5 Gy (RBE) and 8,0 Gy (RBE), respectively. 
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Figure 4-29: The individual results for the Dmean for the right eye following the introduction of setup errors from 1-5 mm 
are displayed. The figure displays the result for patient I-VI including the mean values across the patient group. The setup 
errors are displayed on the x-axis and the Dmean on the y-axis. The zero shifts correspond to the reference plan. 
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5 DISCUSSION 
5.1 The water phantom study 
To demonstrate how density changes in a proton beam path would affect the proton range 
and depth dose distribution, a treatment planning study was performed on water phantoms 
designed in the treatment planning system. Systematic insertion of volumes assigned with a 
HU value of 1000 (representing bone) and volumes assigned with a HU value of – 1000 
(representing air) was performed and the corresponding changes in the proton range and 
the target volume dose coverage were studied. 
 
By analysing the central beam axis depth doseprofiles, it was demonstrated that the main 
effect of introducing density changes in the beam path was an alteration of the beam 
penetration depth, with somewhat different consequence depending on whether the 
inhomogeneity was induced by volumes of bone or air. Depending on the density of the 
inserted material, the SOBP dose plateau was shifted closer to (bone) or further away (air) 
from the source respectively. The effect was significantly more pronounced when inserting 
air than bone, with the range, represented by the distal position of the d90%, being 
changed, almost linearly, with a factor of !"!" =+0,94 for air and with a factor of !"!" = -0,48 
for bone, both obtained from a polynomial fit function applied on the respective data 
points. The significantly larger change in range, that was observed when inserting volumes 
of air compared to volumes of bone, is due to the differences in the densities in the two 
applied materials, and consequently the differences in their corresponding water equivalent 
density. In a scenario like those investigated in this study, where water is entirely replaced 
with a homogenous material of a different density, the change in range is directly related to 
the water equivalent density of the interposed material. This is expressed by the formula ∆𝑅 = 𝑡 − 𝑡𝜌!" where 𝑡 is the physical thickness in units of length, and 𝜌!"is the water 
equivalent density of the replacing material (19) (s 101).  
  
The distal slope of the depth dose profiles was unperturbed by the change in density which 
was introduced proximal to the target volume, this demonstrated by the unaltered distal 
dose fall-off (d80%-d20%). However, the slope of the curves in the entrance region – 
proximal to the SOBP plateau– was altered, reflecting a change of the dose deposition in 
this region. The change depended both on the variation in density (bone versus air versus 
water) and on the position in depth for the inserted air and bone volumes. According to 
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the Bethe-Bloch formula, the energy loss a proton experience when traversing a material is 
proportional to the density of the material (17). Bone, being a more dense material than 
water, consequently increases the energy loss for protons per unit of traversed matter 
relative to the energy loss for protons traversing water, when all other conditions and 
parameters are unchanged. Air is a less dense material than water, and accordingly this in 
turn has the consequence a decrease in the energy loss per unit of traversed air relative to 
water. Thus, when the proton beam hits the bone, the energy deposition increases in the 
region covered by bone, followed by a decrease when the proton beam is entering water 
again. Similarly, dose deposition decreases while the proton beam traverses the air 
compared to water, and increases again in the region with water.  
 
In the second part of the water phantom study the aim was to investigate how a geometric 
misalignment of a target volume with respect to the beam, would affect the proton dose 
distribution. The situation was investigated in both the homogenous and the 
heterogeneous phantoms and simulated by introducing isocenter shifts parallel and 
orthogonal to the beam direction. It was found that isocenter shifts parallel to the beam 
direction (along the y-axis) had no major impact on the dose distribution for both 
homogeneous and heterogeneous phantoms. Since, in this situation, the density along the 
particle path was not changed relative to the situation with no shifts, the water equivalent 
density remained the same and the particle range was not affected (1). Thus the impact on 
the dose distribution here was insignificant. The loss in the 95% target coverage found in 
phantom Awater after the isocenter shifts orthogonal to the beam direction, was solely 
caused by a spatial shift of the dose distribution towards the shift directions. This resulted 
in the target volume being partly shifted “out” of the 95 % dose level at the opposite side. 
An additional disturbance in the dose distributions were seen in the heterogeneous 
phantoms, with decreased homogeneity due to the appearance of hot-and cold spots inside 
the target volume, as well a large cold spots at the distal border of the target volume. Two 
factors contribute to the observed effects. Firstly, and the most important factor, was that 
the isocenter shift was perpendicular to the beam direction, thus resulting in a 
misalignment of the heterogeneity in the centre of the phantom relative to the beam. The 
shift caused the proton beam to traverse through a material with different density, hence 
altering the initially estimated particle range and the corresponding dose distribution.  
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The second effect, described by Goitein (52) and referred to in the ICRU report 78 (19, p. 
102), is known as the edge scattering effect. The edge scattering occurs in situations where 
the media irradiated is partly intersected with a material of different density. The effect is a 
result of the different amount of multiple scattering processes that occurs in the involved 
materials. In the border region between the two materials, the scattering processes that 
occurs in the most dense material will scatter the protons laterally, thus into the less dense 
material. This results in hot spots to occur at the least dense side. Consequently, because 
more protons are scattered laterally away from the denser region, cold-spots occur on the 
side with highest density. Since air hardly scatters protons at all, the edge scattering effect 
was significantly more pronounced in phantom Cair, than in phantom Bbone, given that the 
density difference between water and air is larger than the density difference between water 
and bone. The edge scattering effect could also be observed in the reference plans in 
phantom Bbone and Cair. 
 
 
5.2 Robustness analysis of craniospinal treatment plans 
Craniospinal treatment plans were created with the IMPT technique on 6 anonymous 3D 
CT image data sets of pediatric patients, which have previously had been treated with 
conventional radiation therapy using a combination of photon and electron treatment 
fields. The IMPT treatment plans were used as reference plans in the investigation of the 
dosimetric effect of calibration curve errors and setup errors.  
 
All of the craniospinal reference treatment plans had PTV dose coverage of high 
conformity and homogeneity, and satisfied in general the plan evaluation criteria stated in 
this study. Excellent dose conformity and homogeneity in craniospinal proton treatment 
plans have been previously demonstrated for both the IMPT technique (47) and the 
passive scattering technique (6, 7, 49) and thus confirms the present findings in this study.  
 
Dose sparing was achieved with respect to the normal tissue distal to the target volume and 
for the OAR situated at a certain distance from the PTV. This was expected due to the 
advantageous physical characteristics of the proton beam, and is associated with the rapid 
dose fall-off behind the Bragg Peak plateau, which, in turn, is one of the main rationales 
for using protons for the craniospinal irradiation (6, 7). The doses to the OARs in 
proximity of the target volume did, not surprisingly, receive higher doses, with the highest 
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doses provided to the eyes and the thyroid. The results from the evaluation of the doses to 
the heart, the lungs and the kidneys in the reference treatment plans, agreed reasonable well 
with the findings from other studies, in which it was applied age specific target volumes 
and similar beam arrangements. The doses to the thyroid, however, were generally higher 
in this study than reported elsewhere (6, 7, 49), and varied considerably across the patient 
group with the Dmean ranging from 8% to 31,9% of the prescribed dose. As a comparison, 
Giebeler et al. reported Dmean to the thyroid of 1.5 % of the prescribed dose in their study 
(49). The differences between the study from Giebeler et al and this study can be explained 
by the fact that in this study the thyroid was not assigned with dose-volume objectives 
during the optimization process, and hence not specifically constrained in terms of the 
dose level. In the study of Giebeler et al, however, the thyroid was assigned a constraint 
that imposed the 5 % isodose line not to cross the medial boundary of the thyroid contour, 
this achieved by thickening the compensator in that particular area. Furthermore, due to 
slightly different beam arrangements, the thyroid in this study was covered by the lateral 
oblique cranial fields, as opposed to in the study of Giebeler et al., where the thyroid was 
situated in the area covered by the upper spinal field, shielded by both the lateral and the 
distal field boundary and hence benefitted from the favourable sharp dose gradient behind 
the Bragg Peak dose plateau.  
 
Another noteworthy observation from this study is the considerable spread in the doses to 
the OAR across the patient group, as opposed to the small spread in dose for the target 
volume doses. This can be explained by the large span in size of the defined volume. 
 
The analysis of the effects of the calibration curve errors revealed no substantial 
amendments in the overall doses to the target volumes. The dose alterations in the spinal 
canal were in general negligible, neither undershoot nor overshoot affected the 95% dose 
coverage.  This was not unexpected as all the treatment plans were created with an age-
specific CTV, thus encompassing the spinal canal with a large “margin” distally. 
Furthermore, a 5 mm margin was added at the proximal end of the spinal canal when 
designing the PTV. A more surprising observation was that there was no degradation of 
the 95% dose coverage of the CTV volume distal in the vertebral area, as one would expect 
when introducing range errors. The observed loss in the 95% CTV dose coverage appeared 
exclusively in the brain area. The reference plans were however created including a distal 
field specific range margin of 2 mm, this defined relative to the PTV. Thus the 95% 
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isodose line conformed around the distal part of the vertebra at a distance of approximately 
1-2 mm. The applied margin was sufficient in maintaining the 95% dose coverage at this 
area, regardless of the imposed range errors of 1% to 5%.   
 
The overshoot and undershoot exhibited somewhat different effects with respect to the 
doses to the brain. The overshoot caused a small, but systematic decrease in the overall 
doses, however no degradation of the 95% dose coverage was observed. Compared to the 
reference plan, undershoot resulted in an increased dose inhomogeneity in the brain, this 
was also the case for the overshoot, however to a much smaller extent. Following the 
imposed calibration curve error of +5%, an area of loss in the 95% dose coverage emerged 
along the inside of the cranium, particularly towards the lateral sides (Figure 4-14c)). This 
observed effect typically arises from a situation where the HU values from the planning CT 
are underestimated during the calculation of the proton beam range in the patient (42). The 
subsequent consequence is that the planned positions of the Bragg Peaks in depth are 
abridged. Thus, the loss in the 95% dose coverage observed at the left side of the brain in 
Figure 4-14c), originated from the shortened proton range of the right lateral oblique 
beam, and conversely, the band of cold spots observed at the right side, derived from the 
shortened proton range of the left lateral oblique beam.  
 
The OARs included in the dosimetric evaluations in this study were the heart, the eyes, the 
kidneys and the thyroid. It was found that only tissues distal to, and in close proximity to 
the target volume were affected by the calibration curve error. Further, the overshoot and 
undershoot induced opposing effects. The overshoot is stemming from the overestimation 
of the HU values from the planning CT used for the calculation of the proton beam range 
in the patient (42). This result in the planned positions of the Bragg Peaks in depth being 
prolonged and accordingly the high dose area is moved distally. From the analysis of the 
doses to the OARs it was demonstrated that for the thyroid the result of this positional 
change in the high dose area, was a substantial increase in the doses. The result revealed 
that a 3% overshoot lead to a mean increase of the Dmean in the order of approximately 
47%. This is an important finding, considering that the radiation induced thyroid 
dysfunctions following craniospinal irradiation in pediatric patients, are well documented 
(53, 54).  
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In this study the dosimetric effect of calibration curve errors of ±1% to ±5% was 
evaluated. However, the range error arising from the planning CT is considered to be in the 
order of 3% to 5%, and common values applied in the calculation of uncertainty margins in 
clinical practice, ranges from 2,5% to 3,5% (40). The calibration curve is typically generated 
by the stoichiometric method, previously described in 2.4.1, which provides a good 
estimation of the proton stopping power. Another method, referred to as the direct-fit 
method, utilizes measurements of the test materials in both the CT scanner and in a proton 
beam when generating the calibration curve. By making image- and site-specific calibration 
curves based on the direct-fit method, the range uncertainty arising from the planning CT 
can be reduced to ±1% to ±2% of the range (36, p. 429). 
 
The uncertainty in the conversion from HU values to proton stopping power relations 
derives from the different mechanism of energy loss experienced by photons and protons 
traversing a material. The proton stopping power values depends on the physical density, 
chemical composition and the mean excitation energy (denoted I) of the traversed material.  
The HU values are directly derived from the photon linear attenuations coefficients and 
the HU values are depending on the parameters applied during the CT acquisition. Hence, 
there is no simple one-to-one relationship between the proton stopping power and the HU 
values (33). Considerable efforts are currently being made in the development of a proton 
CT, which possibly could reduce the range uncertainty to less than ±1%. A proton CT 
utilizes the proton beam itself in the image acquisition. By irradiating the patient with low-
intensity proton beams of high energy (330 MeV), and subsequently measure the position, 
direction and energy loss of each departing proton, the volumetric distribution of the 
relative stopping power of the protons can be reconstructed. The technique is intended to 
be used both in treatment planning and for verification of proton range prior to treatment 
(55).   
 
The analysis from this present study showed that the setup errors had negligible impact on 
the doses to the spinal canal. Further, only moderate reductions in the 95% dose coverage 
could be observed for the CTV and the brain. Small areas of underdosage were seen, but 
for both the brain and the CTV the V95% was > 97%, this was found irrespective of any 
setup errors.  
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The underdosage following the induced lateral setup error appeared exclusively at the edge 
of the CTV in the vertebral area, as demonstrated in Figure 4-18b), and was caused by a 
rigid shift of the dose distribution. Thus, a lateral expansion of the irradiated area with e.g. 
an additional CTV-PTV margin would eliminate the present loss in 95% dose coverage. As 
previously also demonstrated in the water phantom simulations (Figure 4.6), the shifting of 
the patient perpendicular to the beam resulted in some additional dose deteriorations. The 
proton range in the patient is determined by the diverse tissue along the beam path. The 
lower density conditions in the lungs, compared to the density conditions in the spine, 
resulted in the edge scattering effect described above, this again resulting in an increase in 
the dose in the lung area. Furthermore, the proton range was prolonged and hence the 
position of the Bragg peaks. As a result the energy deposition was moved distally in the 
patient. This latter effect explains the increased heart doses, which was observed following 
the setup errors in the left directions.  
 
It has been revealed in previous studies that complex tissue heterogeneities, such as the 
bone-tissue-air relations in the head, induce both large dose perturbations due to multiple 
coulomb scattering, which result in a substantial less steep slope of the distal fall-off of the 
Bragg Peaks, and an alteration of the proton range (56, 57). In the current study this effect 
was demonstrated by the increased amount of hot spots and cold spots, which were 
present, especially in the skull basis area, both in the reference treatment plans, and in plans 
with the imposed setup- and calibration curve errors (Figure 4-12, Figure 4-19 and Figure 
4-20).  
 
The analysis of the dosimetric effect of the setup errors on the OARs yielded individual 
patient results with a reasonable consistency between the patients, despite the initial quite 
large spread of the dosimetric values. However, some differences were observed regarding 
the sensitivity to the imposed setup errors. This was mainly related to the size of the 
volumes of the OAR.  
 
The scenarios investigated in this study are mimicking situations that normally will occur in 
the clinical situations during radiation treatment with protons. Similar errors and 
misalignments of a proton beam as e.g. investigated with the water phantoms, can in a 
clinical situation be caused by anatomical changes in the patient, like for instance the 
occurrence of air pockets in the intestines, filling of air cavities in the head and neck area or 
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geometric deviations causing a bony structure to be moved into or out of, or move relative 
to the beam, amongst other. The obtained results clearly illustrate the challenge of how to 
manage such uncertainties during proton therapy, due to the sharp distal SOBP dose edge 
and the sensitivity for heterogeneities characteristic for proton particles.  
 
From radiotherapy with photons the concept of CTV–PTV margins has emerged. The 
purpose of the margin is to ensure sufficient dose coverage to the CTV, despite the 
random and systematic variations that occur during the course of treatment. The margins 
are often determined on the basis of institution dependent knowledge about the 
distribution of setup errors and organ motion for different treatment regions (11, 58). 
However, the results from the present study confirm that this strategy cannot fully be 
adopted in order to manage uncertainties in proton therapy. The geometrical errors itself 
are modality independent and possible to be managed with a CTV-PTV margin. However, 
as demonstrated, setup errors can cause large density changes in the beam path. The effect 
that differences between calculated and actual density in a treatment situation will have on 
the proton particle range, necessitates an additional margin in the beam direction. This 
implies different CTV-PTV margins laterally and in depth, with the consequence that PTV 
would have to be designed individually for each beam direction (19). With the passive 
scattering technique, the PTV is discarded and instead the field parameters are determined 
relative to the CTV.  The managing of uncertainties is solved by building the uncertainty 
margins into the field- and patient-specific blocks and compensators for each beam 
direction (38). With the active scanning technique, the concept of beam specific PTVs has 
been investigated and performed favourable compared to the conventional PTV consept, 
however, this approach is, at present time, only applicable in single field optimized 
treatment plans (59). Considering IMPT and the managing of the uncertainty issues, work 
has been done for implementing range and setup uncertainties into the IMPT optimization 
process. This is referred to as robust optimization (28).  
 
It is a strength to this study that the method used to simulate and estimate the potential 
effects of the range- and setup errors, is well known, evaluated and recommended as a 
simple and useful tool for analysing the sensitivity of a treatment plan for the specified 
errors (13, 14, 60).  
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This study has however some limitations. Firstly, only single errors were considered, which 
do not fully reflect the reality in a clinical situation where the patient position, the patient 
geometry and the density composition is a product of combination of rotational errors, 
setup errors, interfield errors, organ motion, range errors and anatomical deformations. 
Secondly, only a few selected errors were studied, applying a small study group, this limits 
the strengths of the results.  
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6 CONCLUSION AND OUTLOOK 
In this study the effects of density changes in the beam path, setup errors and calibration 
curve errors were investigated. The study showed that the density changes could cause 
severe alterations of the proton range. No large reductions in the 95% dose coverage to the 
target volumes were found, following the introduction of calibration curve errors or setup 
errors. However, in areas of complex tissue density heterogeneities error-induced dose 
disturbances occurred with increased amount of hotspots and cold spots. For OAR in 
close proximity to the target volumes, large increase in doses was observed.  
 
Several interesting challenges regarding craniospinal treatment plans could be addressed in 
future projects: 
 
• The investigation of the sensitivity of the junction area in craniospinal treatment 
plans for interfield motions. 
• The investigation of the potential effects of rotational errors and organ motions on 
the proton dose distribution in craniospinal treatment plans. 
• The investigation of robustness optimization methods in craniospinal treatment 
planning.  
 
In addition; the variation in patient anatomy is one of the most important uncertainties in 
proton therapy, and could cause large changes in the delivered dose distribution compared 
to the planned dose distributions. Studies, with the aim of developing adaptive strategies to 
deal with anatomical changes should be conducted.  
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